INDUCTION OF THE HEAT SHOCK RESPONSE TO PROTECT AGAINST POLYGLUTAMINE DISEASES AND THE ROLE OF PROTEIN SUMOYLATION IN LAMINOPATHIES AND ALZHEIMER\u27S DISEASE by Zhang, Yu-Qian
University of Kentucky 
UKnowledge 
University of Kentucky Doctoral Dissertations Graduate School 
2008 
INDUCTION OF THE HEAT SHOCK RESPONSE TO PROTECT 
AGAINST POLYGLUTAMINE DISEASES AND THE ROLE OF 
PROTEIN SUMOYLATION IN LAMINOPATHIES AND ALZHEIMER'S 
DISEASE 
Yu-Qian Zhang 
University of Kentucky, yzhane@uky.edu 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Zhang, Yu-Qian, "INDUCTION OF THE HEAT SHOCK RESPONSE TO PROTECT AGAINST POLYGLUTAMINE 
DISEASES AND THE ROLE OF PROTEIN SUMOYLATION IN LAMINOPATHIES AND ALZHEIMER'S DISEASE" 
(2008). University of Kentucky Doctoral Dissertations. 632. 
https://uknowledge.uky.edu/gradschool_diss/632 
This Dissertation is brought to you for free and open access by the Graduate School at UKnowledge. It has been 
accepted for inclusion in University of Kentucky Doctoral Dissertations by an authorized administrator of 
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
ABSTRACT OF DISSERTATION 
 
 
 
 
 
 
 
 
 
Yu-Qian Zhang 
 
 
 
 
 
 
 
The Graduate School 
 
University of Kentucky  
 
2008
INDUCTION OF THE HEAT SHOCK RESPONSE TO PROTECT AGAINST 
POLYGLUTAMINE DISEASES AND THE ROLE OF PROTEIN SUMOYLATION IN 
LAMINOPATHIES AND ALZHEIMER’S DISEASE 
 
 
 
 
ABSTRACT OF DISSERTATION 
 
 
 
A dissertation submitted in partial fulfillment of the requirements 
 for the degree of Doctor of Philosophy in the 
College of Medicine at the University of Kentucky 
 
 
By 
 
Yu-Qian Zhang 
Lexington, Kentucky 
 
Director: Dr. Kevin D. Sarge, Professor of Biochemistry  
Lexington, Kentucky 
 
2008 
Copyright © Yu-Qian Zhang 2008
ABSTRACT OF DISSERTATION 
 
 
 
INDUCTION OF THE HEAT SHOCK RESPONSE TO PROTECT AGAINST 
POLYGLUTAMINE DISEASES AND THE ROLE OF PROTEIN SUMOYLATION IN 
LAMINOPATHIES AND ALZHEIMER’S DISEASE 
 
Heat shock proteins function as molecular chaperones which help protein folding 
and prevent protein aggregation.  My study shows that celastrol, a pharmacological 
compound capable of up-regulating the levels of heat shock proteins, inhibits cell death 
and protein aggregation caused by expanded polyglutamine containing protein, and the 
protective effects of celastrol are dependent on heat shock factor 1.  These results 
suggest the potential of celastrol as a therapeutic agent in the treatment of polyglutamine 
diseases. 
 
Sumoylation is a protein modification which plays diverse roles in regulating the 
target proteins.  My study shows that lamin A is a target of protein sumoylation, and two 
lamin A mutants associated with familial dilated cardiomyopathy, E203G and E203K, 
exhibit decreased sumoylation.  My results also indicate that sumoylation is important 
for the normal localization of lamin A, and support a role for altered sumoylation in the 
underlying molecular mechanism of cardiomyopathies associated with the E203G/E203K 
lamin A mutations. 
 
In the third project, my results show that amyloid precursor protein is another 
target of SUMO modification, and sumoylation of amyloid precursor protein reduces the 
levels of amyloid β aggregates, which are the primary causative factor for Alzheimer’s 
disease.  My results provide a new mechanism for the generation of amyloid β, and 
indicate the potential of up-regulating activity of the cellular sumoylation machinery as 
an approach against Alzheimer’s disease.  My results also provide the first 
demonstration that SUMO E2 enzyme exists in the lumen of the endoplasmic reticulum, 
extending the sub-cellular reach of sumoylation to include the regulation of proteins in 
secretory pathways. 
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Preface 
 
There are four chapters in this dissertation, with the first three chapters addressing 
three major projects I have finished during my graduate study.  The first project resulted 
in the paper “Celastrol inhibits polyglutamine aggregation and toxicity through induction 
of the heat shock response” (1), which has been published by Journal of Molecular 
Medicine, the second project resulted in the paper “Sumoylation regulates lamin A 
function and is lost in lamin A mutants associated with familial cardiomyopathies”, which 
has been accepted by Journal of Cell Biology, and the third project led to another paper 
“Sumoylation of amyloid precursor protein negatively regulates Aβ aggregate levels”. 
 
These three projects are independent of each other, as are the first three chapters 
of this dissertation.  Chapter 1 is about the heat shock response and polyglutamine 
diseases, Chapter 2 is about sumoylation of lamin A and laminopathies, and Chapter 3 
addresses sumoylation of amyloid precursor protein and Alzheimer’s disease.  Because 
Chapter 2 and Chapter 3 both involve protein sumoylation, there is a section in the 
beginning of Chapter 2 giving necessary background of this field.   
 
Since all three chapters involve protein aggregation and aging associated diseases, 
in Chapter 4 “Concluding Remarks”, the possible roles of cellular protective mechanisms, 
such as the heat shock response and protein sumoylation, in human aging are discussed.
Chapter 1 The heat shock response and polyglutamine diseases 
 
Heat shock proteins (hsps) are protective against the harmful effects of mutant 
expanded polyglutamine containing proteins that occur in polyglutamine diseases such as 
Huntington’s, prompting the search for pharmacologic compounds that increase hsp 
expression in cells as potential treatments for these diseases.  My experimental results 
show that celastrol, a compound recently shown to up-regulate hsp gene expression, 
significantly decreases killing of cells expressing mutant polyglutamine protein.  This 
effect requires the presence of the transcription factor responsible for mediating inducible 
hsp gene expression, HSF1, and is correlated with decreased amounts and increased 
sodium dodecyl sulfate (SDS) solubility of polyglutamine aggregates.  These results 
suggest the potential of celastrol as a therapeutic agent in the treatment of human 
polyglutamine expansion diseases. 
 
Section 1.1 Background 
Section 1.1.1 Polyglutamine diseases  
 
Polyglutamine diseases are neurodegenerative diseases including Huntington’s 
disease, dentatorubral pallidoluysian atrophy (DRPA), spinobulbar muscular atrophy, and 
spinocerebellar ataxia (SCA) types 1, 2, 3, 6, 7, and 12 (2, 3).  These diseases are caused 
by expanded CAG/ polyglutamine repeats in diseases genes.  For example, Huntington’s 
disease is causes by expanded CAG/ polyglutamine repeats in the huntingtin gene, CAG 
tracts of less than 35 repeats are not pathogenic, however, when the number of repeats is 
above 40, the individuals with these mutant huntingtin genes will invariably develop the 
disease (4), which is characterized by personality changes, motor impairment, and 
subcortical dementia (5).  
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Mutant expanded polyglutamine containing protein causes cytotoxicity by 
different means (Figure 1.1).  In Huntington’s disease, expanded polyglutamine repeats 
result in conformational change of huntingtin protein, and the misfolded protein can be 
recognized and degraded by ubiquitin – proteasome system (UPS).  After degradation, 
the fragments containing expanded polyglutamine repeats form β-sheet structures, 
oligomers, and further large insoluble protein aggregates.  These mutant forms of 
huntingtin proteins may impair the function of UPS, leading to the accumulation of more 
misfolded proteins (6), and damage the function of mitochondria, causing more severe 
cytotoxicity (7).  The fragments containing expanded polyglutamine repeats can also 
enter nuclei, and form large insoluble nuclear inclusions, resulting in the impairment of 
protein transcription (8). 
 
Polyglutamine protein aggregates in brains of patients and transgenic animals 
have been found to contain various molecular chaperones, ubiquitin, and components of 
the 20S proteasome (9, 10).  This suggests that neuronal cells recognize the protein 
aggregates as abnormally folded and try to disaggregate or degrade the mutant proteins 
by recruiting chaperones and proteasomal components (11).  Consistent with this view, 
increased expression of hsp70 and other heat shock proteins (hsps) has been found to be 
effective in reducing the toxicity of mutant polyglutamine proteins, suggesting the 
potential of pharmacological up-regulation of hsp gene regulation as a means for treating 
polyglutamine expansion diseases (12-15). 
 
Section 1.1.2 Heat shock proteins and heat shock factor 1 
 
Heat shock proteins function primarily as molecular chaperones, facilitating 
protein folding, preventing protein aggregation, and targeting misfolded proteins to 
degradation pathway.  For example, hsc70 regulates folding of nascent proteins and 
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transport of proteins to organelles, hsp70 responds to cellular stress induced increases in 
protein misfolding and aggregation, refolding denatured proteins or targeting them for 
proteasome degradation. 
 
The levels of hsps are low under normal conditions, and dramatically up-regulated 
upon stress such as heat stress.  Heat shock factor 1, HSF1, is the transcription factor 
responsible for up-regulating the expression of hsp70 and other hsp genes in response to 
cellular stress (16, 17).  HSF activation involves stress-induced conversion of this factor 
to its trimeric DNA-binding form (18-21).  The activated trimeric HSF1 then binds to 
heat shock elements in the promoters of hsp genes to up-regulate their transcription, 
ultimately leading to elevated levels of cytoprotective hsps in these cells. 
 
The function of HSF1 as a key positive regulator of hsp expression, coupled to the 
observed ability of hsp proteins to protect cells from polyglutamine toxicity prompted the 
hypothesis that interventions that lead to activation of HSF1 could provide protection for 
cells against this toxicity and possibly represent agents that could be useful in treating 
polyglutamine expansion diseases such as Huntington’s (14, 22).  Consistent with this 
hypothesis, expression in cells of a constitutively active mutant HSF1 protein results in 
decreased polyglutamine toxicity and aggregate formation in both cell culture and animal 
models (23, 24).  These and other results have stimulated the search for pharmacological 
compounds capable of up-regulating hsp gene expression. 
 
Section 1.1.3 Celastrol induces the heat shock response 
 
In 2001, National Institute of Neurological Diseases and Stroke created a drug 
library containing more than one thousand compounds, and distributed this library to 27 
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laboratories to blindly test the relevance of these drugs to neurological diseases by 
various assays.  From these assays, celastrol was found to be a hit. 
 
Celastrol is a quinone methide triterpene (Figure 1.2), extracted from the Chinese 
herbal Celastraceae family of plants, and extracts containing celastrol have been given to 
Chinese patients for many years without known toxicity or carcinogenicity, indicating 
that celastrol could be adapted to treat neurological diseases rapidly. 
 
From these assays, celastrol was found to activate HSF1, including inducing DNA 
binding, phosphorylation, and transcriptional activity of HSF1 (22).  Celastrol has also 
been found to inhibit the cytotoxicity of expanded polyglutamine form of huntingtin exon 
1 (25) and androgen receptor (26), but these studies did not examine the mechanism by 
which celastrol protects cells from expanded polyglutamine protein cytotoxicity. 
 
Based on the ability of celastrol to activate HSF1, we proposed our hypothesis 
that celastrol can protect cells against expanded polyglutamine caused protein 
aggregation and cytotoxicity by induction of the heat shock response.   
 
Section 1.2 Materials and methods 
Section 1.2.1 Plasmids, cell culture, and celastrol 
 
The expression constructs encoding Q19-YFP, Q57-YFP, and Q81-YFP were 
kindly provided by Dr. James Burke (Duke University).  The polyglutamine-YFP 
(Qn-YFP) vectors were constructed using CAG repeats that were synthesized by 
polymerase chain reaction (PCR) from human dentatorubral pallidoluysian atrophy 
(DRPLA) cDNAs containing different CAG repeats.   
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HeLa cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Cellgro) supplemented with 10% fetal bovine serum (FBS) and 50 μg/ml gentamicin.  
PC12 cells were cultured in DMEM medium (Cellgro) supplemented with 5% FBS and 
10% heat-inactivated horse serum (Gibco), and 100 units/ml Penicillin-Streptomycin 
(Gibco).  HSF1+/+ and HSF1−/− mouse embryo fibroblast (MEF) cells (kindly 
provided by Dr. Ivor Benjamin, University of Utah) were cultured in DMEM medium 
(Cellgro) supplemented with 10% FBS, 1× Penicillin-streptomycin (Gibco), and 1× 
Non-essential amino acids (Gibco).  
 
Transfection was performed using Effectene transfection reagent (Qiagen), 
following the manufacturer’s protocol.  Celastrol (Calbiochem) was dissolved in 
dimethyl sulphoxide at a stock concentration of 5.54 mM.  
 
Section 1.2.2 Trypan blue cell viability assay and statistical analysis 
 
Cells were collected by centrifugation at 1,000 rpm for 10 min at 4°C (Heraeus # 
3057 rotor), and the pellet was washed twice with 1× phosphate-buffered saline (PBS).  
The cell pellet was then resuspended in 1× PBS to a concentration of approximately 106 
cells/ml.   
 
A 1:1 dilution of the suspension was prepared using a solution containing 0.4% 
trypan blue stain (Gibco), and the suspension was then loaded into the counting chamber 
of a hemocytometer.  The number of stained cells as well as the total number of cells 
was counted, and the percentage of stained cells was taken to represent the percentage of 
cell death.  Experiments were repeated three times.  
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Statistical significance was determined using the Student’s t test.  A P value of 
<0.05 was considered to be statistically significant. 
 
Section 1.2.3 Fluorescence microscopy 
 
Cells were seeded on coverslips, and 48 h after transfection, Hoechst 33342 and 
verapamil were added to the medium to final concentrations of 5 and 50 μg/ml, 
respectively.  After incubation at 37°C for 30 min, the medium was removed, and the 
coverslips washed with 1× PBS for 5 min.  A solution containing 3.7% 
paraformaldehyde in 1× PBS was added, and after 20 min incubation at room temperature, 
coverslips were washed with 1× PBS for 5 min.   
 
Coverslips were washed briefly three times in distilled water and mounted onto a 
slide spotted with 15 μl Vectashield (Vector Laboratories).  Excess fluid was wicked 
from the coverslip and the edges of the coverslip sealed with fingernail polish.  The 
fluorescence was then visualized using a Nikon fluorescent microscope and pictures 
taken with a Nikon Spotcam digital-imaging camera.  
 
To quantify the formation of polyglutamine aggregates, visual fields which 
contained similar numbers of cells (based on the density of nuclei stained by Hoechst) 
were chosen under 20× objective, and then the number of cells that contained aggregates 
in each field of vision was counted.  Three different visual fields were quantified in each 
case.  There were approximately 300 cells in each visual field for the experiments 
involving HeLa cells and PC12 cells, and approximately 100 cells in the experiments 
involving MEF cells.  We scored a cell as positive if it had any visible aggregates, and 
the aggregates in the majority of cells appeared to be intranuclear or perinuclear. 
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Section 1.2.4 Extract preparation and Western blot assay 
 
Cell lysis was performed on ice for 30 min in 50 mM Tris–HCl [pH 8.0], 100 mM 
NaCl, 5 mM MgCl2, 0.5% NP40 lysis buffer (27) containing 1× protease inhibitor 
cocktail (Roche), and 1 mM phenylmethanesulfonyl fluoride added.  To examine hsp70 
level, the cell lysate was cleared by centrifugation at 1,000 rpm at 4°C for 10 min 
(Heraeus # 3332 rotor), and the protein concentration of the supernatant was then 
determined by BioRad assay following Bio-Rad company product manual.  Five 
micrograms of protein extract was subjected to sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and Western blot following standard procedures (28).  
 
The antibodies and dilutions used to probe the Western blots were as follows. 
Anti-hsp70 (stress-induced form; Stressgen) was used at 1:10,000, anti-β-actin antibody 
(Sigma) was used at 1:10,000, and the anti-green fluorescent protein (GFP) polyclonal 
antibody (Bethyl labs) was used at a dilution of 1:4,000.  Hsp70 Western blots were 
quantified using ImageQuant software.  
 
Section 1.2.5 Filtration assay and SDS solubility assay 
 
Cell lysis was performed on ice for 30 min in the lysis buffer described above. 
The insoluble fraction was obtained by centrifugation of the cell lysate at 14,000 rpm at 
4°C for 10 min (Heraeus # 3332 rotor).  The pellet was resuspended in DNase buffer 
(20 mM Tris–HCl [pH 8.0], 15 mM MgCl2, and 0.5 mg/ml DNase I), followed by 
incubation at 37°C for 1 h. After DNase treatment, the protein concentration was 
determined by analyzing an aliquot using the BioRad assay.   
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The incubation was terminated by adjusting the mixtures to 20 mM 
ethylenediamine tetraacetic acid (EDTA), 2% sodium dodecyl sulfate (SDS), and 50 mM 
dithiothreitol and boiling for 5 min.  Thirty micrograms of protein was diluted into 
200 μl 2% SDS, and this was then filtered through a 0.2-μm pore size cellulose acetate 
membrane (Schleicher & Schuell) that was equilibrated with 2% SDS using a Dot-Blot 
system (Schleicher & Schuell).  Filters were washed twice with 200 μl 0.1% SDS and 
then the membrane was blocked and immunoblotted with anti-GFP polyclonal antibody 
as in a regular Western blot (29).  
 
To perform the SDS solubility assay, cell lysates were prepared as described 
above for the filtration assay, including the 14,000 rpm centrifugation of the cell lysate 
and DNase treatment and protein concentration determination by BioRad assay.  Forty 
micrograms of protein was then adjusted to 2× SDS-PAGE sample buffer (62.5 mM 
Tris·HCl [pH 6.8], 10% glycerol, 2% SDS, 5% β-mercaptoethanol) and boiled for 5 min 
after which the sample was analyzed by SDS-PAGE and Western blot with anti-GFP 
polyclonal antibody.  
 
Section 1.3 Results 
Section 1.3.1 Celastrol protects against polyglutamine toxicity  
 
The experimental system we chose to test for effects of celastrol on polyglutamine 
aggregation and toxicity is transfection of a Q57-YFP fusion protein into cell lines (gift 
of Dr. James Burke), which is an established model for the aggregation of polyglutamine 
containing proteins in vivo (30).  Consistent with this, the Q57-YFP protein forms 
clearly visible aggregates upon expression in HeLa cells, while cells transfected with 
Q19-YFP exhibit a diffuse pattern (Figure 1.3).  
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     A previous study showed that 8 h of celastrol treatment leads to increased levels of 
the hsp70 protein (22).  As the studies described later include cell death and aggregation 
assays performed at 48 h after transfection with the Q57-YFP construct, we wanted to 
ensure that cells treated with celastrol treatment for longer times also exhibit elevated 
hsp70 expression.   
 
As shown in Figure 1.4 (upper panel), celastrol treatment of HeLa cells for 24 or 
48 h both result in a dose-dependent increase in expression of the hsp70 protein.  
Quantification of these hsp70 Western blot results indicates that the induction of hsp70 by 
each celastrol concentration is very similar at 24 and 48 h, showing that treatment with 
this drug results in a sustained increase in hsp70 levels (lower panel).  
 
Next, to test whether treatment with this drug confers protection from 
polyglutamine toxicity, HeLa cells were transfected with the Q57-YFP construct and then 
incubated in media containing different concentrations of celastrol.  The results of this 
experiment, shown in Figure 1.5, reveal that celastrol treatment is associated with a 
significant decrease in death of these cells expressing this mutant polyglutamine protein. 
 
Section 1.3.2 Celastrol decreases the amount and increases the solubility of 
polyglutamine aggregates 
 
To determine whether the ability of celastrol to protect cells from polyQ toxicity 
could be mediated via effects on polyQ aggregates, we then examined whether celastrol 
treatment alters the amount of polyQ aggregates in cells and/or their solubility.  The 
results of these experiments show that treatment with celastrol is associated both with a 
decrease in the number of cells containing Q57-YFP aggregates, as quantified by 
fluorescence microscopy (Figure 1.6, panel a), and also with an increase in the amount of 
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Q57-YFP that can be solubilized from aggregates by SDS treatment (Figure 1.6, panel b).  
SDS solubility of aggregates is related with their toxicity, and data from previous studies 
suggests that molecular chaperones may ameliorate the neurodegenerative effect of 
mutant polyglutamine protein, at least in part, by increasing the solubility of these 
proteins (13, 31).  
 
Together, the results shown in Figures 1.5 and 1.6 indicate that celastrol treatment 
decreases the death of cells expressing mutant polyglutamine protein and also decreases 
the number of cells containing Q57-YFP-aggregates and the insolubility of 
Q57-YFP-aggregates. 
 
Section 1.3.3 Protective effects of celastrol treatment in PC12 cells 
 
As the deleterious effects of expression of mutant polyglutamine proteins are 
observed primarily in cells of neuronal origin, we next sought to test the effect of 
celastrol treatment on polyglutamine toxicity and aggregation in PC12 cells.  As shown 
in Figure 1.7 a, PC12 cells are very sensitive to killing by expression of the Q57-YFP 
protein, but celastrol treatment results in a significant decrease in death of these cells.  
As was observed in the experiments using HeLa cells, treatment of PC12 cells with 
celastrol resulted in a significant decrease in the number of cells containing 
polyglutamine aggregates (Figure 1.7 b) and an increase in the amount of Q57-YFP that 
can be solubilized from aggregates by SDS treatment (Figure 1.7 c).  Interestingly, the 
concentrations of celastrol required to achieve these effects on polyglutamine toxicity and 
amount and solubility properties of aggregates in PC12 cells were significantly lower 
than that needed for HeLa cells. 
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Section 1.3.4 Protective effects of celastrol require HSF1 
 
Inducible hsp expression is thought to be important for the ability of cells to 
decrease polyglutamine toxicity and aggregation (12-15).  Consistent with this 
hypothesis, HSF1−/− MEFs (32) that are transfected with Q57-YFP exhibit a higher 
incidence of cell death than HSF1+/+ MEF cells (Figure 1.8 a).  The HSF1−/− MEFs 
also show increased Q57-YFP aggregation, both as measured by number of cells 
containing aggregates (Figure 1.8 b) and by amount of aggregated Q57-YFP protein 
present in cell extracts detected by filtration assay (Figure 1.8 c). 
 
Based on previous results showing the ability of celastrol to activate HSF1 
leading to increased hsp gene expression (22), we hypothesized that this drug’s ability to 
decrease polyglutamine toxicity and aggregation shown by the results above could be 
mediated via the HSF1-regulated gene expression pathway.  
 
To test this hypothesis, we compared the effect of celastrol treatment on 
polyglutamine toxicity and aggregation in the HSF1+/+ vs HSF1−/− MEF cells.  
Celastrol does not exhibit any toxicity in HeLa cells at 1.6 μM, but we found its optimal 
concentration in MEF cells to be lower than that of HeLa cells.  Thus, for these 
experiments, we used 0.4 μM celastrol treatment, which has no toxic effect in either 
HSF1−/− or wild-type MEFs.  First, Western blot analysis shows that the HSF1−/− cells 
are unable to up-regulate hsp70 protein expression in response to celastrol treatment, 
demonstrating that celastrol-induced up-regulation of hsp70 expression is mediated by 
the HSF1-regulated gene expression pathway (Figure 1.9 a). 
 
To test the contribution of HSF1-regulated pathways in the protective effects of 
celastrol against polyglutamine aggregation and toxicity, we transfected HSF1+/+ and 
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HSF1−/− MEF cells with Q57-YFP in combination with celastrol treatment and then 
measured the amount of cell death and levels of aggregated Q57-YFP.  
 
The results of this experiment show that, as it did for the HeLa and PC12 cells, 
celastrol treatment resulted in decreased death of HSF1+/+ MEF cells transfected with 
Q57-YFP, but did not protect the HSF1−/− cells (Figure 1.9 b).  Consistent with these 
results, the HSF1+/+ cells, but not the HSF1−/− cells, showed decreased levels of 
aggregated Q57-YFP upon celastrol treatment, as measured by the filtration assay (Figure 
1.9 c).  These results suggest that the HSF1 protein plays an important role in the 
protective effects of celastrol against polyglutamine toxicity and aggregation. 
 
Section 1.3.5 Celastrol induces the heat shock response in mice 
 
The results shown above suggest that celastrol and other drugs that activate HSF1 
could have potential as therapeutic agents for treating polyglutamine expansion diseases.  
To support this idea, we determined to examine if celastrol can induce the heat shock 
response in different tissues of mice. 
 
All procedures with mice were approved by the lnstitutional Animal Care and Use 
Committee at University of Kentucky.  Mice were injected with 3 mg/kg celastrol.  
After 1 hr, 3 hrs, 6 hrs, 12 hrs, 24 hrs, or 48 hrs, mice were euthanasized with CO2, 
different tissues were taken, immediately frozen on dry ice and stored at −80°C.  To 
evaluate the levels of hsp70 induction, the tissues were homogenized in cell lysis buffer 
described previously by 20 strokes with dounce homogenizer.   
 
As shown in Figure 1.10 a, celastrol treatment can induce hsp70 expression in 
mouse brain 12 hours after injection.  Figure 1.10 b shows the quantitative result of 
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hsp70 induction obtained with three groups of mice.  Celastrol treatment can also induce 
hsp70 expression in mouse kidney, as shown by Figure 1.10, panels c and d.  Injection 
of celastrol also increases the levels of hsp70 in other tissues of mice, including liver and 
testis (data not shown).   
 
Based on these results, celastrol can induce the heat shock response in vivo.  
Especially, celastrol induces hsp70 expression in mouse brain, suggesting that celastrol 
can cross the blood brain barrier, which is essential for a drug to be used for treating 
neurological diseases.   
 
Section 1.4 Discussion 
Section 1.4.1 Celastrol protects against polyglutamine toxicity 
 
The results described above indicate that the drug celastrol is able to decrease 
polyglutamine toxicity, supporting the proposal that this drug could potentially be useful 
in the treatment of Huntington’s disease and possibly other human polyglutamine 
expansion disorders.  The results also show that lower concentrations of celastrol are 
required for its protective effects against polyglutamine toxicity in PC12 cells, cells with 
neuronal characteristics, compared to other cell types.  A particularly beneficial aspect 
of this drug is that it is already being used to treat people with other disorders, and thus it 
could likely be adapted more quickly for use in treating polyglutamine expansion 
diseases than other drugs not currently being used in humans. 
 
Results presented in this paper indicate that the protective effect of celastrol 
against polyglutamine toxicity is associated with decreased numbers of cells containing 
aggregates as well as increased SDS-solubility of the mutant polyglutamine protein.  
This might seem to be at odds with findings that formation of polyglutamine aggregates 
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can be protective for cells expressing these mutant proteins (33-35).  However, our 
results are consistent with the findings of a number of studies which indicate that 
molecular chaperones can reduce the formation of polyglutamine aggregates and increase 
the solubility of expanded polyglutamine proteins (12-15, 23, 24).  Molecular 
chaperones could be acting at multiple levels to reduce polyglutamine toxicity, but one 
possibility that has been proposed is that these chaperones, and by extension celastrol 
through its HSF1-mediated up-regulation of chaperones, may be acting at an early step to 
prevent formation of toxic intermediates before they can become part of larger aggregates. 
This would explain both how celastrol treatment protects cells from polyglutamine 
toxicity and the effects we observe on polyglutamine aggregates in the celastrol-treated 
cells.  
 
An alternative explanation that must be considered, in keeping with previous 
studies indicating that aggregate formation can be protective for cells, is that the results 
we observe relating celastrol with the numbers of cells containing polyglutamine 
aggregates could be due, at least in part, to a potential ability of celastrol to enhance the 
survival of cells that do not contain aggregates, which would then lead to a perceived 
decrease in the numbers of cells containing aggregates in our experiments.  Our data do 
indicate, however, the protective effects of celastrol with respect to polyglutamine 
toxicity. 
 
Section 1.4.2 Celastrol affects multiple cellular signaling pathways 
 
Our results suggest that the beneficial effects of celastrol treatment in decreasing 
polyglutamine toxicity are mediated through the action of the HSF1-regulated gene 
expression pathway, based on the finding that celastrol is not protective in Q57-YFP 
transfected HSF1−/− MEF cells (Figure 1.9).  This finding also suggests that other drugs 
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that activate HSF1 could also have potential as candidate therapeutic agents for treating 
polyglutamine expansion diseases. 
 
Celastrol has been reported to have potent anti-peroxidation activity by its 
dienone-phenol moiety and the anionic carboxyl group (36), and a recent paper showed 
that celastrol can activate multiple antioxidant response genes (37).  Celastrol also has 
strong anti-inflammatory activity including inhibiting the activation of nuclear factor 
(NF)-κB pathway, the production of pro-inflammatory cytokines and nitric oxide (38-40).  
Its anti-oxidant and anti-inflammatory activities have been exploited by traditional 
Chinese medicine to treat fever, joint pain, and other inflammatory diseases.  A recent 
study displayed protective effects of celastrol in transgenic mouse model of amyotrophic 
lateral sclerosis, a disease associated with inflammation and oxidative stress (41). 
 
The anti-inflammatory effect of celastrol could be due to its ability to activate 
HSF1 and induce the heat shock response.  Activation of NF-κB pahway involves 
phosphorylation of IκB by IκB kinase (IKK), the heat shock response has been found to 
inhibit IκB phophorylation by inhibiting the activity of IKK, and induction of 
intracellular phosphatase activity (42).  So, it’s possible that celastrol inhibits the 
activation of NF-κB signaling pathway by induction of the heat shock response.  It has 
also been found that mutation of cysteine 179 in the activation loop of IKK can abolish 
the inhibitory effect of celastrol (43).  Further study of celastrol may help dissecting of 
the interaction between heat shock and NF-κB signaling pathways. 
 
The mechanism by which celastrol induces the heat shock response is also 
intriguing.  Celastrol has been known to inhibit topoisomerase II, which is essential for 
DNA replication and repair (44).  Also, celastrol was reported to inhibit the activity of 
the proteasome in vitro and in vivo, resulting in the accumulation of ubiquitinated 
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proteins (45).  All of these effects can lead to cell stress and induction of the heat shock 
response indirectly.  However, based on another study, the chemical structure of 
celastrol is highly specific for induction of the heat shock response, and the effect of 
celastrol is very rapid, unlike the delayed response caused by proteasome inhibitor (22).  
So, it’s possible that celastrol induces the heat shock response by multiple mechanisms 
through its different pharmacological properties.   
 
Heat shock proteins have been reported to inhibit the apoptosis pathway.  For 
example, hsp70 can interact with Apaf-1 and prevent the formation of apoptosome, hsp70 
can also inhibit TNF induced extrinsic pathway (46).  So, celastrol exerts multiple 
neuroprotective effects by induction of the heat shock response, including preventing 
protein aggregation and inhibiting cell apoptosis. 
 
Section 1.4.3 Celastrol as a therapeutic drug for human diseases 
 
Celastrol can induce hsp70 expression in different tissues of mouse including 
mouse brain (Figure 1.10), suggesting the protective effect of celastrol in vivo.  
Induction of the heat shock response has great implications in the treatment of diseases 
associated with protein misfolding.  Various neurodegenerative diseases including 
polyglutamine diseases and Parkinson’s disease are associated with accumulation of 
misfolded proteins which form oligomers, aggregates, fibrils, or plaques.  It has been 
reported that the levels of hsps are down-regulated in aged people (47, 48), so induction 
of the heat shock response provides a therapeutic approach for these diseases.  
 
 The cell protective effects of heat shock proteins also have benefits in the 
treatment of ischemia-reperfusion injury.  Heat shock proteins play a significant role in 
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cardioprotection, and gene transfer of hsp70 has been reported to reduce infarct size 
caused by ischemia-reperfusion in vivo(49).   
 
The ability of celastrol to induce the heat shock response suggests its great 
potential to protect against various cell stress and damages in clinical settings.  To 
support this idea, our lab is carrying on a project to examine if celastrol can protect mice 
against whole body hyperthermia caused mortality.  These experiments will further 
investigate the protective effects of celastrol in vivo, and will provide more evidence for 
the clinical use of celastrol for treating human diseases associated with stress and protein 
misfolding. 
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Figure 1.1 Molecular pathogenesis of Huntington’s disease.  This figure is from Landles 
et al. (2004) (50). 
 
 
 
 
Figure 1.2 Structure of celastrol.  This figure is from Calbiochem product data sheet for 
celastrol. 
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Figure 1.3 Aggregation of polyglutamine -YFP proteins in cells.  HeLa cells were 
transfected with constructs expressing Q19-YFP (A), Q57-YFP (B), or Q81-YFP (C), 
48 h later, nuclei were stained with Hoechst and the formation of aggregates visualized 
by fluorescence microscopy. 
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Figure 1.4 Hsp70 protein level is increased by celastrol treatment.  HeLa cells were 
treated with the indicated concentrations of celastrol for 24 or 48 h, after which cell 
extracts were made and subjected to Western blot using antibodies against hsp70 or 
β-actin (upper panel).  These results were quantified using the ImageQuant program, 
and the values for the two treatment times, grouped by celastrol concentration, were 
graphed (lower panel). 
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Figure 1.5 Celastrol treatment reduces Q57-YFP cytotoxicity.  HeLa cells were 
transfected with Q57-YFP along with celastrol treatment at the concentrations indicated.  
After 48 h, the amount of cell death was determined by trypan blue assay.  Data are 
shown as means ± SE (*P < 0.007, **P < 0.004, ***P < 0.0001, for each celastrol 
concentration treatment vs no celastrol). 
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Figure 1.6 Celastrol treatment reduces number of cells containing Q57-YFP aggregates 
and increases Q57-YFP solubility.  HeLa cells were transfected with Q57-YFP along 
with celastrol treatment at the concentrations indicated.  a After 48 h of transfection, the 
formation of Q57-YFP aggregates was quantified using fluorescence microscopy.  
Visual fields which contained similar numbers of cells (based on the density of nuclei 
stained by Hoechst) were chosen under 20× objective.  Three different visual fields were 
quantified in each case, and data are shown as means ± SE (*P < 0.004, **P < 0.001, 
***P < 0.0003, for each celastrol concentration treatment vs no celastrol).  b To 
determine the amount of Q57-YFP monomer that could be solubilized from aggregates in 
lysates of the transfected cells by SDS treatment, the protein concentration of the 
insoluble fraction of the cell lysates was determined, and then 40 μg of protein was 
subjected to SDS solubilization treatment, followed by Western blot using anti-GFP 
antibody. 
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Figure 1.7 Celastrol effects on Q57-YFP toxicity and aggregates in PC12 cells. PC12 
cells were transfected with Q57-YFP along with celastrol treatment at the concentrations 
indicated.  After 48 h, the amount of cell death was determined by trypan blue assay (a), 
the number of cells containing Q57-YFP aggregates was quantified using fluorescence 
microscopy (b), and the amount of Q57-YFP monomer solubilized from aggregates by 
SDS treatment visualized by Western blot using anti-GFP antibody (c).  In a and b, data 
are shown as means ± SE (*P < 0.0001 and **P < 0.0001 (a), *P < 0.001 and **P <
0.0001 (b), in each case for each celastrol concentration treatment vs no celastrol). 
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Figure 1.8 HSF1−/− cells exhibit higher Q57-YFP aggregation and cell death. HSF1−/− 
and wild-type MEF cells were transfected with Q57-YFP, and after 48 h, cell death was 
examined by trypan blue assay (a), and the number of cells containing Q57-YFP 
aggregates was quantified using fluorescence microscopy (b), or filtration assay, in which 
30 μg of the insoluble fraction was filtered through 0.2 μm cellulose acetate membrane, 
and the aggregates retained on the membrane were immunoblotted using anti-GFP 
antibody (c).  In a and b, data are shown as means ± SE.  *P < 0.008 (a); *P < 0.003 
(b). 
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Figure 1.9 Celastrol decreases Q57-YFP toxicity and aggregation in wild-type but not 
HSF1−/− MEF cells.  a Celastrol treatment does not induce hsp70 expression in 
HSF1−/− cells.  Wild-type and HSF1−/− MEF cells were treated with no celastrol or 
0.4 μM celastrol, and after 12 h, cell extracts were made, and 5 μg protein was loaded 
into each lane for immunoblotting with anti-hsp70 antibody.  b and c Wild-type and 
HSF1−/− MEF cells were transfected with Q57-YFP, with celastrol at the indicated 
concentrations added at the same time.  After 48 h, cell death was examined by trypan 
blue assay (b), with data shown as means ± SE (*P < 0.002 for HSF1+/+ 0.4 μM celastrol 
vs no celastrol; *P < 0.002 for HSF1−/− 0.4 μM celastrol vs no celastrol), and amount of 
aggregated Q57-YFP was determined by filtration assay followed by anti-GFP Western 
blot (c). 
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Figure 1.10 Celastrol induces hsp70 expression in mice.  Mice were injected with 3 
mg/kg celastrol intraperitoneally, and control mice were injected with equal volume of 
DMSO.  The levels of hsp70 in mouse brain (a) and kidney (c) were examined by 
western blot using anti-hsp70 antibody.  The results were quantified using the 
ImageQuant program, and the values obtained with three groups of mice were graphed 
for mouse brain (b) and kidney (d).  Data are shown as means ± SE. 
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Chapter 2 Sumoylation of lamin A and laminopathies 
 
Lamin A mutations cause many diseases, including cardiomyopathies and 
Progeria Syndrome.  Covalent attachment of SUMO polypeptides regulates the function 
of many proteins, but no examples of human disease-causing mutations occurring in a 
sumoylation consensus sequence to alter sumoylation were known.  Here we show that 
lamin A is sumoylated at lysine 201, and that two lamin A mutants associated with 
familial dilated cardiomyopathy, E203G and E203K, exhibit decreased sumoylation.  
E203 occupies the conserved +2 position in the sumoylation consensus ΨKXE.  E203G, 
E203K, and K201R lamin A mutants exhibit a similar aberrant subcellular localization, 
and are associated with increased cell death.  Fibroblasts from an individual with the 
E203K lamin A mutation also exhibit decreased lamin A sumoylation and increased cell 
death.  These results suggest SUMO modification is important for normal lamin A 
function, and implicate a role for altered sumoylation in the E203G/E203K lamin A 
cardiomyopathies. 
  
Section 2.1 Background  
Section 2.1.1 Protein sumoylation  
 
Covalent attachment of Small Ubiquitin-like Modifier (SUMO) proteins to lysine 
residues in target proteins, or sumoylation, is an important regulator of protein functional 
properties.  SUMO is composed of 97 amino acids, its structure is similar to ubiquitin, 
and the mechanism of protein sumoylation is quite similar to ubiquitination.   
 
There are four enzymatic steps in the process of sumoylation, including 
maturation, activation, conjugation, and ligation (51, 52).  As shown in Figure 2.1, in 
the first step, SUMO protein is cleaved by SUMO specific carboxyl terminal hydrolase to 
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generate a carboxyl-terminal diglycine motif.  Then the mature SUMO is conjugated to 
SUMO activating enzyme E1, and then E1 transfers SUMO to E2 conjugating enzyme 
ubc9.  In the last step, SUMO is transferred from ubc9 to target protein, and forms an 
isopeptide bond between the terminal glycine of SUMO and the ε-amino group of a 
lysine on the target protein.  And the last step can happen with the help of E3 ligase 
(53). 
 
On contrary to the similarity of structure and enzymology between SUMO and 
ubiquitin, the function of protein sumoylation is quite different from ubiquitination, 
which promotes degradation of proteins.  Depending on the protein targets, sumoylation 
can affect subcellular localization of proteins, protein protein interaction, DNA binding 
and transactivation function of transcription factors (51-53). 
 
RanGAP1, which plays an important role in the regulation of nuclear transport, is 
the first identified target for protein sumoylation.  Unsumoylated RanGAP1 localizes in 
the cytoplasm, and after sumoylation, it associates with the cytoplasmic fibers of the 
nuclear pore complex (NPC) (54, 55).  Components of the sumoylation machinery, 
including E2 conjugating enzyme ubc9 and E3 ligase RanBP2, have also been found at 
the NPC (56, 57), suggesting that proteins can be sumoylated when they are transported 
through the nuclear pore, and the events of protein sumoylation and nuclear transport 
may be correlated.  
 
There are three different forms of SUMO proteins, SUMO-1, SUMO-2 and 
SUMO-3.  SUMO-2 and SUMO-3 are more similar, with 97% identity to each other in 
the primary sequence, what’s more, SUMO-2 and SUMO-3 have internal SUMO 
consensus sites allowing the formation of polymeric SUMO chains (58).  Some distinct 
functions have been identified for different SUMO parologs.  For example, RanGAP1 is 
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preferentially modified by SUMO-1 (59), topoisomerase II is preferentially modified by 
SUMO-2/3 (60), whereas the promyelocytic leukemia protein can be modified by all 
three SUMO paralogs (61, 62). 
 
Section 2.1.2 Lamin A and laminopathies 
 
Lamin A is a component of nuclear lamina, which is beneath inner nuclear 
membrane, and plays an important role in the maintenance of nuclear shape, spacial 
organization of nuclear pores, and regulation of DNA replication and transcription. 
 
Lamins are classified as two types, A-type and B-type.  A-type lamins are 
expressed in differentiated tissues, whereas B-type lamins are expressed at all stages of 
development (63).  Lamins are composed of a N-terminal head domain, an α-helical 
central rod domain, and a globular C-terminal tail domain (64), they can form dimers via 
the central rod domain, and the dimers can then polymerize to form higher order 
structures (65).  There are two major A-type lamin species, lamin A and lamin C, which 
arise from the alternative splicing of LMNA transcript (66, 67). 
 
As shown in Figure 2.2, lamin A and lamin A-associated proteins have been 
known to cause many human diseases termed laminopathies, including muscular 
dystrophies, cardiomyopathy, and lipodystrophy (68).   
 
One example of laminopathies is Hutchinson-Gilford progeria syndrome (HGPS), 
which is a premature aging disease of children.  The most frequent mutation of LMNA in 
HGPS is a C→T mutation at position 1824, which results in a 50 aa deletion near the C 
terminus (69).  In HGPS cells, the mutant lamin A (progerin) accumulates at nuclear 
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periphery (70, 71), A-type and B-type lamins form heteropolymers instead of 
homopolymers as in the wildtype cells (72), and the nuclei have a reduced deformability.  
 
Lamin A has been reported to interact with important transcription factors, such 
as retinoblastoma protein (73) and sterol regulatory element binding protein 1 (SREBP1) 
(74).  Familial partial lipodystrophy (FPLD) is a laminopathy showing loss of 
subcutaneous adipose tissue.  In FPLD, mutant lamin A proteins accumulate at nuclear 
envelope, resulting in the sequestration of SREBP1, which is involved in the regulation 
of cholesterol biosynthesis and adipogenesis (75). 
 
Section 2.1.3 Lamin A is a possible target of sumoylation 
 
Using a yeast two-hybrid screen, a previous study identified an interaction 
between lamin A and ubc9, the SUMO E2 enzyme (76).  Based on this interaction, we 
hypothesized that the lamin A protein could be a target of sumoylation. 
 
We did a sequence analysis for the lamin A protein with the software called 
SUMOplot, and identified a SUMO consensus sequence around K201, and more 
interestingly, mutations of E203 in this SUMO consensus sequence, E203G and E203K, 
have been shown to cause familial dilated cardiomyopathy, although the underlying 
molecular mechanism was unclear (77, 78).   
 
We proposed the hypothesis that lamin A can be sumoylated at K201, and 
E203G/K mutations in the SUMO consensus sequence result in the defect of sumoylation, 
and that this is the mechanism underlying familial dilated cardiomyopathy caused by the 
E203 mutations. 
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Section 2.2 Materials and methods 
Section 2.2.1 Cell culture and plasmids 
 
HeLa cells were cultured in DMEM medium (Cellgro) supplemented with 10% 
FBS and 1x antibiotic-antimycotic (Gibco, 100x) in 5% CO2.  Human skin fibroblasts 
(generously provided by Dr. Ray Hershberger, University of Miami) were cultured in the 
same media supplemented with 2mM glutamine.  Transfection of HeLa cells was 
performed using Effectene transfection reagent (Qiagen), following the manufacturer’s 
protocol.  Immunoprecipitation analysis and fluorescence microscopy were performed 
48 hrs after the transfection.   
 
The GFP-lamin A plasmid was constructed from the pcDNA3.1-LMNA plasmid 
(generous gift of Dr. Nanbert Zhong, New York State Institute for Basic Research in 
Developmental Disabilities).  The coding region of the lamin A protein was cut out with 
EcoRI and BamHI digestion, and ligated into pEGFP-C2 vector (Clontech).  
Mutagenesis PCR was performed to generate GFP-Lamin A K201R, E203G, and E203K 
mutants.  The primers used for the mutagenesis were as follows (only top primers are 
listed, bottom primers are the reverse complements of each of these): 5’-CTG CAG ACC 
ATG AGG GAG GAA CTG GAC-3’ for K201R, 5’-ACC ATG AAG GAG GGA CTG 
GAC TTC CAG-3’ for E203G, 5’-ACC ATG AAG GAG AAA CTG GAC TTC CAG-3’ 
for E203K.  Plasmids were sequenced by Davis Sequencing, and all plasmids were 
prepared using Qiagen plasmid purification kit following Qiagen product manual.  
HA-SUMO-1 and HA-SUMO-2 were expressed using pcDNA3-HA-SUMO-1 and 
pcDNA3-HA-SUMO-2 plasmids (kindly provided to us by Dr. Kim Orth, UT 
Southwestern Medical Center).   
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Section 2.2.2 Immunoprecipitation and Western blot 
 
For immunoprecipitation experiments, the cell pellets of two plates of the 
transfected HeLa cells were re-suspended in 500 µl RIPA buffer (150 mM NaCl, 50 mM 
Tris-HCl pH 7.4, 1% NP-40, 0.2% SDS, 0.25% sodium deoxycholate, 1mM EDTA), with 
1x protease inhibitor cocktail (Roche), 1 mM DTT, 20 mM N-ethylmaleimide (added 
fresh).  Cell lysis was performed by sonication after which the sample was incubated on 
ice for 20 min.  After centrifugation at 10,000 rpm, 4◦C for 10 min (Heraeus # 3332 
rotor), the supernatant was transferred to a fresh tube, and 20 µl of the whole cell lysate 
was removed for analysis of the level of transfected GFP-Lamin A.   
 
300 µl of 50% Protein G Sepharose slurry (Amersham Biosciences) was washed 3 
times with PBS, and re-suspended in RIPA buffer to make a 50% slurry.  The cell lysate 
was precleared by mixing it with 150 µl of this slurry and 5 µg goat IgG, and incubating 
at 4◦C for 60 minutes.  After centrifugation at 4,000 rpm, 4◦C for 1 minute (Heraeus # 
3332 rotor), the supernatant was transferred to a fresh tube, and mixed with 5 µg 
anti-GFP antibody (Bethyl Inc.).  After incubation at 4◦C for 60 minutes, 150 µl of 50% 
Protein G Sepharose slurry was added and incubated at 4◦C for 60 minutes.  The beads 
were washed with RIPA buffer 4 times, and then boiled in 50 µl 4x SDS-PAGE loading 
buffer.  After brief centrifugation, the supernatants were subjected to SDS-PAGE and 
Western blot using the antibodies described below. 
 
Similar procedures were followed for endogenous IP with HeLa cells, the human 
skin fibrablasts, or mouse heart, except that mouse IgG was used for preclear, and 
anti-lamin A antibody (BD Transduction Labs) was used for immunoprecipitation. 
 
SDS-PAGE and Western blot were performed following standard procedures (28).  
The antibodies and dilutions used to probe the western blots were as follows.  Goat 
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anti-GFP antibody (Bethyl) was used at 1:2,000, mouse anti-HA antibody (gift from Dr. 
Doug Andres lab, University of Kentucky) used at 1:2,000, goat anti-SUMO-1 antibody 
(Bethyl, Inc.) used at 1:1,000, rabbit anti-SUMO-2 antibody (Abgent) used at 1:500, and 
rabbit anti-lamin A antibody (Abcam) used at 1:500. 
 
Section 2.2.3 Fluorescence and immunofluorescence microscopy 
 
Cells were seeded on coverslips.  At 48 hours after transfection with the 
wildtype or point mutant GFP-lamin A expression constructs, Hoechst 33342 and 
verapamil were added to the medium to final concentrations of 5 µg/ml and 50 µg/ml, 
respectively.  After incubation at 37◦C for 30 minutes, the coverslips were washed twice 
with PBS, and then incubated in 3.7% paraformaldehyde at room temperature for 20 
minutes.  After two washes with PBS and a wash with distilled water, the coverslips 
were wicked on a kimwipe to partially dry, and then mounted onto a slide spotted with 15 
µl Vectorshield (Vector Labs).   
 
For immunostaining, after two washes with PBS the coverslips were incubated in 
PBS containing 3% BSA at 37◦C for 1 hour, and then incubated with rabbit anti-lamin A 
antibody (Abcam, 1:1,000) at 37◦C for 30 minutes.  After the coverslip was washed 
twice with PBS, it was incubated with Fluorescein anti-rabbit IgG (1:200) at 37◦C for 30 
minutes.  After two washes with PBS and a brief wash with distilled water, the coverslip 
was mounted onto a slide spotted with 15 µl Vectorshield (Vector Laboratories).  
 
 Excess fluid was wicked from the coverslips, and the edges of the coverslip 
sealed with fingernail polish.  The fluorescence was then visualized using a Leica TCS 
SP5 confocal microscope, or Nikon fluorescent microscope with a Nikon Spotcam 
digital-imaging camera.  Figures were made from the images using Adobe Photoshop. 
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Section 2.2.4 Trypan blue cell viability assay 
 
Cells were collected by centrifugation at 1,000 rpm for 10 minutes at 4ºC 
(Heraeus # 3057 rotor), and the pellet was washed twice with PBS.  The cell pellet was 
then resuspended in PBS to a concentration of approximately 106 cells/ml.  A 1:1 
dilution of the suspension was prepared using a solution containing 0.4% trypan blue 
stain (Gibco), and the suspension was then loaded into the counting chamber of a 
hemacytometer.  The number of stained cells as well as the total number of cells was 
counted, and the percentage of stained cells was taken to represent the percentage of cell 
death.  Three data sets were analyzed for each experiment. 
 
Statistical significance was determined using the Student t-test.  A P value of 
<0.05 was considered to be statistically significant. 
 
Section 2.2.5 Preparation of cardiomyocytes 
 
All animals and animal procedures used in this study were approved by the 
University of Kentucky Institutional Animal Care and Use Committee.  E16 mouse (ICR 
outbred strain, Harlan) hearts were dissected free of connective tissues, and ventricles 
were separated from atria.  Cells were enzymatically dispersed and cultured as 
previously described (79).  Briefly, 10 embryos were minced and quickly transferred to 
nominally Ca2+-free digestion buffer containing 0.5 mg/mL collagenase (type II, 
Worthington) and 1 mg/mL pancreatin for two 15-minute cycles.  Digested tissue yielded 
a large fraction of single spontaneously beating cells in DMEM medium (Cellgro) 
supplemented with 10% FBS and 1x antibiotic-antimycotic (Gibco, 100x). 
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Section 2.3 Results 
Section 2.3.1 Lamin A is sumoylated at lysine 201 by SUMO-2 
 
First, we sought to test for sumoylation of endogenous lamin A by performing 
immunoprecipitation of HeLa cells extracts using lamin A antibody followed by Western 
using antibodies against SUMO-1 or SUMO-2.  The results suggest that lamin A is 
SUMO-modified, and that it is preferentially modified by SUMO-2 compared to 
SUMO-1 (Figure 2.3 A).  The results in Figure 2.3 C indicate that lamin A protein in 
extracts of mouse heart is also sumoylated and that, like lamin A present in HeLa cell 
extracts, SUMO-2 appeared to be the predominant SUMO protein attached to this 
protein. 
 
Analysis of the lamin A amino acid sequence revealed a match to the sumoylation 
consensus sequence ΨKXE (MKEE) surrounding lysine 201 in the rod-containing 
domain of lamin A (Figure 2.4, top panel).  To test whether sumoylation of lamin A is 
occurring at lysine 201, HeLa cells were transfected with mammalian expression 
plasmids encoding GFP-fusion constructs of wildtype lamin A and lamin A in which this 
lysine was changed to a non-sumoylatable arginine (K201R), along with expression 
constructs encoding HA-tagged SUMO-1 or SUMO-2.  Extracts of the transfected cells 
were subjected to immunoprecipitation with anti-GFP antibody followed by anti-HA 
Western blot.   
 
The results of this experiment, in agreement with the results obtained for 
endogenous lamin A, indicated that the wildtype lamin A protein is covalently modified 
by SUMO-2, but not as efficiently sumoylated by SUMO-1 (Figure 2.4, lower panel).  
The results also show that the modification by SUMO-2 is not observed for the K201R 
lamin A mutant protein, suggesting that lysine 201 is the site of SUMO-2 attachment in 
this protein. 
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Section 2.3.2 Disease associated mutant lamin A proteins exhibit defect of 
sumoylation 
 
The glutamic acid residue at the fourth position in the sumoylation consensus 
sequence ΨKXE is known to be important for the efficiency of SUMO addition to the 
nearby lysine in this sequence (80, 81).  Relevant to this, two different 
disease-associated mutations of the human lamin A gene have been identified which 
change the glutamic acid in the sumoylation consensus sequence (Figure 2.5, top panel).     
Both the E203G and E203K mutations of lamin A are associated with familial dilated 
cardiomyopathy and conduction system disease (77, 78), but the underlying molecular 
mechanism by which these mutations alter lamin A function is not known.  We 
hypothesized that the E203G and E203K mutations could possibly mediate their 
deleterious effects by resulting in decreased sumoylation of lamin A.   
 
To test the feasibility of this hypothesis, we performed the transfection and 
immunoprecipitation experiment similar to that described in Figure 2.4, except that here 
the sumoylation of wildtype GFP-lamin A was compared to that of GFP-lamin A 
constructs containing the E203G or E203K mutations.  The results of this experiment, 
shown in Figure 2.5 (lower panel), indicate that both the E203G and E203K mutant lamin 
A proteins exhibit decreased sumoylation compared to the wildtype lamin A protein. 
 
Section 2.3.3 Sumoylation of lamin A is important for its normal subcellular 
localization 
 
Sumoylation plays an important role in regulating the functional properties of 
target proteins in cells (82-84).  The wildtype lamin A protein exhibits a characteristic 
pattern of localization at the nuclear periphery (68, 85-87).  We hypothesized that 
sumoylation of lamin A at lysine 201 may be important for this localization pattern.   
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To test this hypothesis, HeLa cells were transfected with the wildtype or K201R 
lamin A GFP-fusion expression plasmids, and then examined by fluorescence microscopy.  
As shown in Figure 2.6 A, the wildtype lamin A GFP-fusion protein exhibits the typical 
pattern of relatively continuous nuclear peripheral localization.  However, the K201R 
lamin A GFP-fusion protein shows an altered localization pattern, with the mutant protein 
appearing to concentrate into foci.  These results suggest that sumoylation of lamin A is 
important for the normal pattern of subcellular localization of this protein.  Analysis of 
the subcellular localization of GFP fusion constructs of the E203G or E203K mutant 
lamin A proteins by fluorescence microscopy reveals that both of these mutant proteins 
exhibit altered localization patterns similar to that of the K201R mutant lamin A, in 
which these proteins are concentrated in foci, in contrast to the more continuous 
appearance of the wildtype lamin A at the nuclear periphery (Figure 2.6 A).  The pattern 
we observed for the E203G lamin A is similar to that observed by a previous study (74).  
To our knowledge the localization of the E203K lamin A has not previously been 
reported. 
 
To confirm the effects of altered localization of the cardiomyopathy-associated 
E203G and E203K lamin A mutants in a more physiologically-relevant cell type, we 
repeated the experiments shown above in mouse embryonic cardiomyocytes.  The 
results, shown in Figure 2.6 B, indicate that the K201R, E203G, and E203K lamin A 
mutants all exhibit aberrant localization patterns in the cardiomyocytes compared to 
wildtype lamin A that are similar to those observed in HeLa cells. 
 
In light of the defective sumoylation and aberrant localization patterns of the 
K201R, E203G, and E203K lamin A mutant proteins, we hypothesized that expression of 
these lamin A mutants could result in decreased cell viability.  The results shown in 
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Figure 2.7 indicate that this appears to be the case, as all three of these mutant lamin A 
proteins are associated with increased cell death. 
 
Section 2.3.4 Decreased sumoylation and abnormal localization of lamin A 
in E203K patient cells  
 
In the final set of experiments, we examined skin fibroblasts obtained from a 
patient that is heterozygous for the E203K lamin A mutation, which as described above is 
associated with cardiomyopathy (77).  Immunoprecipitation of lamin A followed by 
SUMO-2 Western blot indicates that, as expected, levels of sumoylation of lamin A are 
reduced in E203K patient cells compared to cells of a normal individual (Figure 2.8 A).  
The patient is heterozygous for the E203K lamin A mutation, thus we expect that lamin A 
sumoylation was decreased but not eliminated.  Further, immunofluorescence analysis 
of lamin A indicated more cells showing abnormal lamin A localization and nuclear 
morphology for the E203K fibroblasts compared to normal fibroblasts (Figure 2.8 B).  
The E203K fibroblasts also exhibit increased cell death compared to the control 
fibroblasts (Figure 2.8 C). 
 
These experiments performed with patient cells verified the above results 
obtained by overexpressing lamin A proteins, and strengthened the disease relevance of 
these results.  
 
Section 2.4 Discussion 
Section 2.4.1 Sumoylation regulates lamin A function and is lost in lamin A 
mutants associated with cardiomyopathy 
 
The results presented in this paper indicate that lysine 201 of lamin A is a target of 
covalent modification by the SUMO-2 protein, and that this sumoylation is important for 
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the normal pattern of subcellular localization of the lamin A protein.  The results of 
these experiments also show that lamin A sumoylation is decreased in transfected mutant 
E203G and E203K lamin A proteins that cause familial dilated cardiomyopathies, and in 
lamin A of fibroblasts of individuals with the E203K mutation.  To our knowledge these 
are the first examples of human disease-causing mutations occurring in a crucial residue 
of a sumoylation consensus sequence and resulting in decreased sumoylation of the 
mutant protein.   
 
The results also indicate that the mutant E203G and E203K lamin A proteins 
exhibit altered subcellular localization patterns that are very similar to that of the SUMO 
attachment site mutant K201R lamin A protein.  These results suggest a role for 
sumoylation in the correct localization of lamin A in the cell.  Further, cells transfected 
with the E203G and E203K lamin A proteins and skin fibroblasts of individuals with the 
E203K mutation exhibit higher levels of cell death compared to cell transfected with 
wildtype lamin A or normal skin fibroblasts, respectively.  Together, these results 
suggest that sumoylation is important for normal lamin A function and support a role for 
altered sumoylation in the underlying molecular mechanism of familial dilated 
cardiomyopathies associated with the E203G/E203K lamin A mutations. 
 
Section 2.4.2 Loss of sumoylation underlies cardiomyopathy caused by 
E203G/K lamin A mutations  
 
Abnormal localization of mutant lamin A proteins could cause nuclear structural 
defects and increased nuclear fragility, which then cause increased mechanical damage to 
cardiac muscle nuclei during repeated muscle contraction.  It has been found that 
LMNA-/- cardiomyocytes display disruption of the muscle-specific desmin network, loss 
of cytoskeletal tension, and defective force transmission (88).   
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How does loss of sumoylation cause abnormal localization of lamin A?  To 
answer this question, we proposed a model as shown in Figure 2.9.  Key enzymes of 
sumoylation machinery localize at the nuclear pore complex (NPC), and sumoylate 
nuclear proteins when they are imported through the nuclear pore (56, 57).  K201R, 
E203G, and E203K mutant lamin A proteins are unable to be sumoylated, so they form 
non-productive stable complexes with ubc9 at the NPC.  Such non-productive 
interactions could lead to the SUMO machinery proteins being pulled by the mutant 
lamin A proteins into the foci, and the concentrated lamin A mutants and SUMO 
enzymes at the NPC may impair the functions of nuclear pores and inhibit the global 
sumoylation of cellular proteins.   
 
This model can be testified by examining if mutant lamin A proteins co-localize 
with ubc9 and components of the NPC, such as Tpr, in the foci, and it is also worth 
studying if the global sumoylation and nuclear transport functions are impaired in cells 
bearing K201R, E203G or E203K lamin A mutation. 
 
Another possible mechanism underlying E203 lamin A mutation caused 
cardiomyopathy is that lamin A mutations may affect the interactions between lamin A 
and other proteins, resulting in disruptions of specific signaling pathways.  Loss of 
sumoylation of lamin A could be responsible for the disruption of protein-protein 
interaction.  SUMO binding motif (V/I-X-V/I-V/I) has been identified in almost all 
proteins involved in SUMO-dependent processes (89).  Based on sequence analysis, we 
identified SUMO binding motif in lamin A and some lamin A interacting proteins, such 
as emerin.  So attachment of SUMO to lamin A may play an important role in the 
interactions between lamin A and other nuclear proteins, and loss of sumoylation of 
E203G and E203K mutant lamin A proteins could result in the disruption of these 
interactions, and defects in some signaling pathways. 
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The complex phenotypes of cardiomyopathies may arise from the combination of 
mechanical and transcriptional regulation defects. 
 
Section 2.4.3 The abnormal phenotypes caused by E203G/K lamin A 
mutations are not likely due to protein conformational change 
 
The results displayed above suggest SUMO modification is important for normal 
lamin A function, and implicate a role for altered sumoylation in the E203G/E203K 
lamin A cardiomyopathies.  However, we can not exclude the possibility that the 
abnormal phenotypes caused by E203G and E203K lamin A mutations could be due to 
conformational change of mutant lamin A proteins.   
 
K201R, E203G, and E203K mutations localize in the coiled-coil domain of lamin 
A, which is important for the dimerization or polymerization of the protein.  The 
mutations in this domain could cause conformational change and disrupt the assembly of 
lamin A proteins into higher order oligomers.  To exclude this possibility, and support 
that loss of sumoylation underlies familial dilated cardiomyopathy caused by E203G and 
E203K mutations, it’ll be a good idea to make another two lamin A mutants E202G and 
E202K.  Theoretically mutations at position +1 in the SUMO consensus sequence 
(ΨKXE) will not affect sumoylation efficiency, so to examine if E202G and E202K 
mutations can cause abnormal localization of lamin A will prove if loss of sumoylation is 
responsible for the abnormal phenotypes caused by E203G and E203K lamin A 
mutations.   
 
In addition, we performed a sequence alignment for mouse lamin A and human 
lamin A proteins, and found a high similarity of the amino acid sequences of these two 
proteins, and interestingly, the SUMO consensus sequence in mouse lamin A is LKEE 
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instead of MKEE in human lamin A protein, suggesting that some flexibility is allowed, 
and change of some amino acid in this site is not necessary to cause conformational 
change of lamin A. 
 
Section 2.4.4 Lamin A interacts with E3 ligase 
 
We performed in vitro translation and sumoylation experiment using recombinant 
E1, ubc9 and SUMO-2 to examine if lamin A protein can be sumoylated in vitro, but we 
failed to get any sumoylated lamin A.  So we speculate that sumoylation of lamin A 
may need the help of some E3 ligase. 
 
  It has been reported that drosophila Su(var)2-10 locus encodes a member of the 
PIAS protein family, and SU(VAR)2-10 proteins colocalize with nuclear lamin (90).  
PIAS family proteins have SUMO E3 activity, they have a RING finger-like structure and 
bind directly to SUMO E2 enzyme ubc9 and some protein targets for sumoylation (91).  
The colocalization between lamin A and SU(VAR)2-10 suggests that SU(VAR)2-10 may 
act as the E3 ligase for lamin A sumoylation. 
 
The interactions between lamin A and SU(VAR)2-10 and ubc9 may suggest 
another possibility that lamin A regulates nuclear protein sumoylation by interacting with 
key sumoylation enzymes.  This is supported by the finding that LMNA mutation 
changes the distribution pattern of SUMO-1 (92).   
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Figure 2.1 Regulation of SUMO modification.  This figure is from Hilgarth et al. (2004) 
(93).  
 
 
Figure 2.2 Lamin A and laminopathies.  This figure is from Vlcek et al. (2007) (94). 
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Figure 2.3 Lamin A is sumoylated by SUMO-2.  (A) Extracts of HeLa cells were 
subjected to immunoprecipitation using anti-lamin A antibody followed by Western blot 
assay using anti-SUMO-1 or anti-SUMO-2 antibodies.  (B)  Western blot assays using 
anti-SUMO-1 or anti-SUMO-2 antibodies were performed on the HeLa cell lysates used 
for the immunoprecipitations to confirm the abilities of these antibodies to detect 
SUMO-1 and SUMO-2, respectively.  (C) Extracts prepared from mouse heart were 
subjected to immunoprecipitation using anti-lamin A antibody followed by Western blot 
assay using anti-SUMO-1 or anti-SUMO-2 antibodies. 
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Figure 2.4 Lamin A is sumoylated at lysine 201 by SUMO-2.  Extracts of HeLa cells 
transfected with GFP-fusion constructs of wildtype lamin A or K201R mutant lamin A 
and HA-tagged SUMO-1 or SUMO-2 plasmids were subjected to immunoprecipitation 
using anti-GFP antibody followed by anti-HA Western blot.  Western blots of the lysates 
using anti-GFP and anti-HA antibodies show levels of GFP-lamin A proteins and 
HA-SUMO-1/HA-SUMO-2 proteins (incorporated into major sumoylated proteins), 
respectively. 
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Figure 2.5 E203G and E203K mutant lamin A proteins exhibit decreased sumoylation.  
The top panel shows the location of the E203G and E203K mutations in lamin A 
associated with familial dilated cardiomyopathy at the conserved glutamic acid residue of 
the SUMO consensus sequence (ΨKXE) surrounding lysine 201.  In the lower panel, 
extracts of HeLa cells transfected with GFP-fusion constructs of wildtype lamin A, 
E203G mutant lamin A, or E203K mutant lamin A along with HA-tagged SUMO-2 were 
subjected to immunoprecipitation with anti-GFP antibody followed by anti-HA Western 
blot.  Levels of transfected GFP-lamin A proteins in the cell lysates were determined by 
Western blot using anti-GFP antibody. 
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Figure 2.6 SUMO-site K201R mutant lamin A and cardiomyopathy-associated E203G 
and E203K mutant lamin A proteins exhibit similar patterns of aberrant localization.  
Wildtype, K201R, E203G, and E203K lamin A GFP-fusion expression plasmids were 
transfected into HeLa cells (panel A) or mouse embryonic cardiomyocytes (panel B), and 
the subcellular localization of the GFP-lamin A proteins examined by confocal 
fluorescence microscopy.  DNA was visualized by staining with Hoechst 33342.  Bars, 
5 µm. 
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Figure 2.7 K201R, E203G, and E203K mutant lamin A proteins are associated with 
increased cell death.  Wildtype, K201R, E203G, or E203K lamin A GFP-fusion 
expression plasmids were transfected into HeLa cells, which were then analyzed by 
trypan blue assay to measure cell death.  Data are shown as means ± SEM (*P<0.0001, 
**P<0.0002, ***P<0.0001, for lamin A mutants vs. wildtype), and are each from 3 data 
sets. 
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Figure 2.8 Fibroblasts from an individual with E203K lamin A mutation exhibit 
decreased lamin A sumoylation, altered lamin A localization/nuclear morphology, and 
increased cell death.  (A) Extracts prepared from skin fibroblasts of a normal individual 
and individual heterozygous for the E203K lamin A mutation were subjected to 
immunoprecipitation using mouse anti-lamin A antibody followed by Western blot assay 
using anti-SUMO-2 antibody or rabbit anti-lamin A antibody .  (B) Normal fibroblasts 
and E203K fibroblasts were subjected to immunofluorescence analysis using anti-lamin A 
antibody.  DNA was visualized by staining with Hoechst 33342.  Bars, 5 µm.  (C) 
Normal fibroblasts and E203K fibroblasts with 50% confluence were analyzed by trypan 
blue assay to measure cell death.  Data are shown as means ± SEM (P<0.0038), and are 
from 3 data sets. 
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Figure 2.9 K201R, E203G and E203K lamin A mutant proteins harm cells by interfering 
with the sumoylation enzymes associated with nuclear pores.  (A) Key enzymes of 
sumoylation machinery localize at the nuclear pore complex (NPC), and protein with 
nuclear localization signal (NLS) get sumoylated when it is imported through the nuclear 
pore.  (B) lamin A mutant proteins form non-productive stable complexes with ubc9, 
leading to the accumulations of SUMO machinery proteins and lamin A mutant proteins 
at the NPC. 
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Chapter 3 Sumoylation of amyloid precursor protein and Alzheimer’s 
disease 
 
The proteolytic processing of amyloid precursor protein (APP) to produce Aβ 
peptides is thought to play an important role in the mechanism of Alzheimer’s Disease.  
Here we show that lysines 587 and 595 of APP, which are immediately adjacent to the 
site of β-secretase cleavage, are covalently modified by SUMO proteins in vivo.  
Sumoylation of these lysine residues is associated with decreased levels of Aβ aggregates.  
Further, overexpression of the SUMO E2 enzyme ubc9 along with SUMO-1 results in 
decreased levels of Aβ aggregates in cells transfected with the familial Alzheimer’s 
disease-associated V642F mutant APP, indicating the potential of up-regulating activity 
of the cellular sumoylation machinery as an approach against Alzheimer’s Disease.   
 
Our results also provide the first demonstration that the SUMO E2 enzyme (ubc9) 
is present within the endoplasmic reticulum, indicating how APP, and perhaps other 
proteins that enter this compartment, can be sumoylated. 
 
Section 3.1 Background 
Section 3.1.1 Alzheimer’s disease and amyloid precursor protein 
 
4.5 million Americans suffer from Alzheimer’s disease (AD).  5% of men and 
women aged between 65 and 74 years old have AD, and half of the people aged above 85 
years old have AD.  AD is named after a German doctor named Alois Alzheimer.  In 
1906, Dr. Alzheimer noticed some abnormal changes in a woman died of an unusual 
mental illness.  In the brain tissue of this woman, he found some abnormal clumps and 
tangled fibers.  Today the abnormal clumps are known as amyloid plaques (95, 96), and 
the tangled fibers are neurofibrillary tangles, and these are two signs of AD.  In the brain 
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of AD patients, nerve cells died in the areas which are essential for memory and other 
mental abilities, and the connections between nerve cells are disrupted. 
 
Accumulation of amyloid β peptides is known to be the primary causative factor 
for AD.  As shown in Figure 3.1, amyloid β (Aβ) is generated from amyloid precursor 
protein (APP), which is a cell membrane protein, and trafficked to cell membrane 
through the constitutive secretory pathway.  During its trafficking, APP undergoes a 
series of cleavage events.  In normal conditions, it is cleaved through α-cleavage 
pathway by α-secretase, and generates a large soluble N-terminal fragment (APPα), and a 
non-amyloidogenic C-terminus (97).  However, APP can also be cleaved through 
β-cleavage pathway by β-secretase, and generate a shorter N-terminal fragment (APPβ), 
and a amyloidogenic C-terminus, which can then be further cleaved by γ-secretase, and 
generate Aβ.   
 
In the β-cleavage event, most of the Aβ peptides are 40 amino acids in length 
(Aβ40), only 10% are 42 amino acids long (Aβ42), depending on the position of 
γ-cleavage.  Aβ42 is more hydrophobic and pathogenic than Aβ40, and is the 
predominant form found in amyloid plaques (98, 99).   
 
Section 3.1.2 The production and pathological role of Aβ 
 
Mutations in APP affect Aβ production.  For example, Swedish mutation, a 
double mutation of amino acids 670 and 671 from Lys-Met to Asn-Lys immediately 
upstream of the β-cleavage site results in a dramatic increase in the production of Aβ 
(100-103).  Also, V717 mutations adjacent to the γ-cleavage site can increase the 
production of the more pathogenic Aβ42 relative to Aβ40 (104).  Transgenic mice 
overexpressing either Swedish mutant or APPV717F produce increased levels of Aβ, and 
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displayed AD associated pathological features such as abnormally hyperphosphorylated 
tau protein, reduced expressions of synaptic marker proteins, microgliosis, reactive 
astrocytosis, and dysfunction of memory (105-109). 
 
Accumulation of Aβ is an early event in the pathogenesis of AD, and Aβ 
aggregates have various pathological effects.  It has been shown that accumulation of 
Aβ results in the impairment of proteasome (110, 111), and the inhibition of proteasome 
function results in higher levels of Aβ aggregates and buildup of tau protein, which is 
found in neurofibrillary tangles (112, 113).  Aβ oligomers can cause dysfunction of long 
term potentiation (LTP), a form of synaptic transmission responsible for memory, in 
hippocampal slice culture, and this dysfunction can be rescued by expressing ubiquitin 
C-terminal hydrolase L1, which is a component of the ubiquitin-proteasome system 
(114). 
 
Section 3.1.3 APP is a possible target for protein sumoylation 
 
Various pieces of evidence have shown that accumulation of Aβ plays an 
important role in the development of AD.  However, the factors that affect Aβ 
production are still unclear.  What kind of factors determine APP cleaved through the 
α-cleavage pathway or β-cleavage pathway?  What is the molecular mechanism 
underlying the increased production of Aβ in cells expressing Swedish mutant?  Why is 
the production of Aβ increased in aged people?  All of these important questions remain 
to be answered. 
 
We performed a sequence analysis with the software SUMOplot, and identified 
two SUMO concensus sequences (ΨKXE), and interestingly, the two possible 
sumoylation sites K587 and K595 are adjacent to the β-cleavage site (M596).  We 
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proposed our hypothesis that APP can be sumoylated at K587 and K595, and that 
sumoylation at these sites can affect the β-cleavage of APP. 
 
Section 3.2 Materials and methods 
Section 3.2.1 Cell culture and plasmids 
 
HeLa cells were cultured in DMEM medium (Cellgro) supplemented with 10% 
FBS and 1x antibiotic-antimycotic (Gibco, 100x) in 5% CO2.  Transfection was 
performed using Effectene transfection reagent (Qiagen), following the manufacturer’s 
protocol.   
 
The 6xHis-APP plasmid was constructed from pCITE-4a (+)-APP695 (kind gift of 
Dr. Iliya Lefterov, University of Pittsburgh).  Mutagenesis PCR was performed to 
generate pCITE-APP K587R, K595R, K587/595R, and V642F mutants.  The 
oligonucleotides used were the following (only top sequence of each pair is shown): 
5’-TTG ACA AAT ATC AGG ACG GAG GAG ATC-3’ for K587R, 5’-ATC TCT GAA 
GTG AGG ATG GAT GCA GAA-3’ for K595R, and 5’-ACA AAT ATC AGG ACG 
GAG GAG ATC TCT GAA GTG AGG ATG GAT GCA-3’ for K587, 595R, and 
5'-GCG ACA GTG ATC TTC ATC ACC TTG GTG-3' for the V642F mutation.  The 
pCITE-APP wildtype and mutants were then digested with BamHI and NotI, and the APP 
fragments were ligated respectively into pAG3-His-APPΔNL plasmid (115) (gift from Dr. 
Paul Murphy, University of Kentucky) which was also digested with BamHI and NotI, 
thereby swapping the Aβ-containing and flanking regions of the plasmids (thus, the 
Swedish mutation is not present in the final 6xHis-APP constructs).  
 
HA-SUMO-1 and HA-SUMO-2 were expressed using pcDNA3-HA-SUMO-1 
and pcDNA3-HA-SUMO-2 plasmids (provided by Dr. Kim Orth), and ubc9 expression 
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was up-regulated in cells using a pcDNA3-ubc9 construct (provided by Dr. Moshe 
Sadofsky, Albert Einstein College of Medicine). 
 
Section 3.2.2 His-tag pull-down of transfected proteins 
 
HeLa cells were transfected with 6xHis-APP wildtype or mutant APP (V642F, 
K587R, K595R, or K587, 595R) constructs along with HA-SUMO-1 or HA-SUMO-2 
expression plasmids.  At 48 hours after transfection, the cells were collected, and the 
cell pellet of two plates of cells was re-suspended in 500 μl pQE buffer (20 mM Hepes, 
pH 7.4, 300 mM NaCl, 2 mM β-mercaptoethanol), with 1x protease inhibitor cocktail 
(Roche), 1 mM PMSF, and 20 mM N-ethylmaleimide added freshly.  Cell lysis was 
performed by sonication 3 times at 20 kHz, followed by incubation on ice for 20 min.  
After centrifugation at 10,000 rpm, 4ºC for 10 minutes (Heraeus # 3332 rotor), the 
supernatant was transferred to a fresh tube, and 80 μl of the whole cell lysate was taken 
for analysis of the level of Aβ and APP whole protein (20 μl for each).  
 
150 μl of 50% Ni-NTA agarose slurry (Qiagen) was washed 3 times with PBS, 
and then added to the cell lysate.  After incubation at 4ºC for 1 hr, the beads were 
washed sequentially with pQE buffers containing 5 mM imidazole, 25 mM imidazole, 
and 50 mM imidazole (each wash was performed twice).  Then, 50 μl pQE buffer with 
250 mM imidazole was added to the beads, and protein was eluted by shaking the beads 
at RT for 30 min.  The supernatant was taken out, mixed with SDS-PAGE loading 
buffer, boiled for 5 minutes, and then analyzed by Western blot with anti-HA antibodies 
as described below. 
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Section 3.2.3 Immunofluorescence microscopy 
 
HeLa cells were seeded on coverslips.  Hoechst 33342 and verapamil were 
added to the medium to final concentrations of 5 μg/ml and 50 μg/ml, respectively.  
After incubation at 37ºC for 30 minutes, the coverslips were washed twice with PBS, and 
then incubated in ice-cold methanol for 3 minutes.  After washing with cold PBS, the 
coverslips were incubated in 3% BSA (made with PBS) at 37ºC for 1 hr.   
 
For immunostaining, the coverslips were incubated with 1:100 dilutions of the 
anti-calnexin and anti-ubc9 antibodies at 37ºC for 30 minutes.  Coverslips were washed 
twice with PBS, and then incubated with Texas Red anti-mouse IgG and Fluorescein 
anti-rabbit IgG (both from Vector Labs) at 37ºC for 30 minutes.  After two washes with 
PBS and a brief wash with distilled water, the coverslip was mounted onto a slide spotted 
with 15 μl Vectorshield (Vector Labs).  Excess fluid was wicked from coverslips, and 
then coverslip edges were sealed with fingernail polish.  
 
Fluorescence was visualized using a Nikon fluorescent microscope and pictures 
taken with a Nikon Spotcam digital camera. 
 
Section 3.2.4 Subcellular fractionation 
 
HeLa cells were collected, and the cell pellets resuspended in 500 μl Buffer A (20 
mM HEPES, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, and 250 
mM sucrose) with 1x protease inhibitor cocktail (Roche) added fresh.  The cells were 
disrupted by dounce homogenization (30 strokes), followed by incubation on ice for 20 
minutes.   
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The cell lysate was then centrifuged at 1,000 g, 4ºC for 10 minutes to pellet the 
nuclei.  The supernatant was transferred to a fresh tube, and centrifuged at 10,000 g, 4ºC 
for 10 minutes to pellet mitochondria and intact Golgi.  After this centrifugation, the 
supernatant was transferred to a fresh tube, and centrifuged at 20,000 g, 4ºC for 10 
minutes to pellet large dense ER vesicles.   
 
The nuclei fraction and membrane fraction containing large dense vesicles were 
washed with Buffer A, and re-suspended in 10 pellet volumes of RIPA buffer (150 mM 
NaCl, 50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.2% SDS, 0.25% sodium deoxycholate, 1 
mM EDTA, 1x protease inhibitor cocktail).  The suspension was then passed through a 
23 gauge needle 20 times, and incubated on ice for 20 minutes.  After centrifugation at 
10,000 rpm, 4ºC for 10 min (Heraeus # 3332 rotor), the supernatant was taken and 
analyzed by SDS-PAGE and Western blot using antibodies that detect ubc9, lamins, and 
calnexin. 
 
Section 3.2.5 Sealed microsome trypsin digestion assay 
 
Sealed, ER-enriched, myelin-depleted calf brain microsomes were isolated as 
previously described (116), except that 10 mM HEPES-NaOH, pH 7.4 was used instead 
of 0.1 M Tris-HCl, pH 7.4.  Microsomes were resuspended in 10 mM HEPES-NaOH, 
pH 7.4, 0.25 M sucrose, 1 mM EDTA to a membrane protein concentration of 10-20 
mg/ml and stored at -20ºC.   
 
The calf-brain microsomal vesicles were incubated at 37ºC for 30 minutes with 
trypsin (trypsin:total protein (w/w) = 1:20) in the absence or presence of 1% Triton 
X-100, and then subjected to SDS-PAGE followed by Western blot using anti-ubc9 
antibodies.  
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Section 3.2.6 Immunoprecipitation and Western blot 
 
Half of the mouse brain was disrupted by dounce homogenization (20 stokes) in 1 
ml RIPA buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.4, 1% NP-40, 0.2% SDS, 0.25% 
sodium deoxycholate, 1mM EDTA), with 1x protease inhibitor cocktail (Roche), 1 mM 
DTT, 20 mM N-ethylmaleimide (added fresh), followed by incubation on ice for 20 
minutes.  After centrifugation at 10,000 rpm, 4◦C, for 10 min (Heraeus # 3332 rotor), the 
supernatant was transferred to a fresh tube. 
 
300 µl of 50% Protein G Sepharose slurry (Amersham Biosciences) was washed 3 
times with PBS, and re-suspended in RIPA buffer to make a 50% slurry.  The cell lysate 
was precleared by mixing it with 150 µl of this slurry and 5 µg rabbit IgG, and incubating 
at 4◦C for 60 minutes.  After centrifugation at 4,000 rpm, 4◦C for 1 minute (Heraeus # 
3332 rotor), the supernatant was transferred to a fresh tube, and mixed with 5 µg 
anti-APP C-terminal rabbit polyclonal antibody (Calbiochem).  After incubation at 4◦C 
for 60 minutes, 150 µl of 50% Protein G Sepharose slurry was added and incubated at 
4◦C for 60 minutes.  The beads were washed with RIPA buffer 4 times, and then boiled 
in 50 µl 4x SDS-PAGE loading buffer.  After brief centrifugation, the supernatants were 
subjected to SDS-PAGE and Western blot using anti-SUMO-1 or anti-SUMO-2 
antibodies. 
 
SDS-PAGE and Western blot were performed following standard procedures (28).  
The antibodies and dilutions used to probe the western blots were as follows.    
Anti-Aβ(1-17) mouse monoclonal antibody (Signet Labs, gift of Dr. Louis Hersh, 
University of Kentucky) was used at 1:1000, anti-APP C-terminal rabbit polyclonal 
antibody (Calbiochem) used at 1:5000, mouse anti-HA antibody (gift of Dr. Doug Andres) 
used at 1:2000, goat anti-SUMO-1 antibody (Bethyl, Inc.) used at 1:1,000, rabbit 
anti-SUMO-2 antibody (Abgent) used at 1:500.   
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The antibodies used that recognize ubc9 and lamin A/C are mouse monoclonal 
antibodies from BD Transduction laboratories, and were used at 1:200 and 1:1000 
respectively.  The anti-calnexin antibody is a rabbit polyclonal antibody (Calbiochem, 
gift of Dr. Skip Waechter, University of Kentucky) used at 1:2000. 
 
Section 3.3 Results 
Section 3.3.1 APP is sumoylated at lysines 587 and 595 
 
As shown in Figure 3.2 a, analysis of the amino acid sequence of APP revealed 
that there are two matches to the sumoylation consensus sequence ΨKXE/D surrounding 
lysines 587 and 595 of this protein (numbered according to the APP695 isoform).  These 
two lysine residues are immediately N-terminal to the β-secretase cleavage site.   
 
To test whether APP is covalently modified by SUMO proteins, and if so, 
whether the modification occurs at lysines 587 and/or 595, HeLa cells were transfected 
with mammalian expression plasmids encoding 6xHis-fusion constructs of wildtype APP 
and APP in which lysines 587 or 595, or both, were changed to non-sumoylatable 
arginines (K587R, K595R, and K587R/K595R), along with an expression construct 
encoding HA-tagged SUMO-1.  The 6xHis tag in these APP constructs is located 
immediately C-terminal to the signal peptide, thereby allowing this 6xHis motif to remain 
after signal peptide cleavage and be used to affinity purify the transfected APP proteins 
using Ni-NTA beads (115).  Thus, extracts of the transfected cells were subjected to 
Ni-NTA affinity chromatography to pull down the transfected 6xHis-tagged wildtype and 
lysine mutant APP proteins, followed by anti-HA Western blot assay to detect potential 
sumoylated forms of the proteins.   
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The results of this experiment suggest that the wildtype APP protein is 
sumoylated as evidenced by the detection of a number of distinct bands by the anti-HA 
antibody (Figure 3.2 b).  The relatively large sizes of some of the sumoylated APP 
forms may reflect the presence of SUMO chains on the proteins, while the most rapidly 
migrating bands could possibly represent SUMO-modified proteolytic fragments of APP.   
The results of this experiment also indicate that the intensity of sumoylated bands is 
slightly decreased for both the K587R and K595R APP mutants compared to wildtype 
APP, and completely abolished in the K587R/K595R double mutant APP protein.  
These results suggest that lysines 587 and 595 of APP are sites of sumoylation. 
 
Section 3.3.2 Sumoylation of APP at lysines 587 and 595 negatively regulates 
levels of Aβ aggregates 
 
As shown in Figure 3.2 a, the lysine 587 and 595 sumoylation sites in APP are 
only 1 and 9 residues, respectively, away from the β-secretase cleavage site.  Based on 
this proximity, we hypothesized that sumoylation at these lysine residues could regulate 
cleavage at this site, thereby potentially modulating levels of Aβ.   
 
To test this hypothesis, we used an antibody against the Aβ peptide to perform 
Western blot assays of extracts of cells transfected with the wildtype or lysine mutant 
(both single and double mutants) APP constructs and HA-SUMO-1 construct in order to 
examine levels of Aβ aggregates in the extracts (117-119).  The results indicate that, 
compared to the extracts of cells transfected with the wildtype APP protein, extracts of 
cells expressing the K587R and K595R single sumoylation site mutant APP constructs 
both exhibit higher levels of Aβ aggregates, which are further increased in those of cells 
expressing the K587R/K595R double mutant APP construct (Figure 3.2 c).  These 
results suggest that sumoylation of APP at lysines 587 and 595 acts to negatively regulate 
levels of Aβ aggregates. 
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Section 3.3.3 Sumoylation of APP by both SUMO-1 and SUMO-2 inhibits the 
generation of Aβ aggregates 
 
The results shown above reveal the presence of the SUMO-1 protein in the 
sumoylated forms of APP.  However, in addition to SUMO-1, cells also express 
SUMO-2 and its closely related homolog SUMO-3.  SUMO-2 and SUMO-3 are both 
able to form SUMO chains via a sumoylation site present in each protein (58, 120).  
Therefore, based on the results in Figure 3.2 b suggesting the existence of SUMO chains 
on APP, we hypothesized that SUMO-2 and/or SUMO-3 could be among the SUMO 
groups attached to APP.   
 
To test this, we performed an experiment identical to that described for Figure 3.2 
b, except that here an HA-SUMO-2 expression construct, instead of an HA-SUMO-1 
construct, was transfected into cells along with the wildtype or lysine mutant (single and 
double) 6xHis-APP plasmids.  The results of this experiment suggest that the 
sumoylated form of APP does contain SUMO-2 in addition to SUMO-1, and lysines 587 
and 595 are both sites of sumoylation (Figure 3.3 a).  The results also support the 
finding that mutating these lysine residues to non-sumoylatable arginines results in 
elevated levels of Aβ aggregates (Figure 3.3 b). 
 
Next, to test whether endogenous APP in brain is sumoylated, we subjected 
extracts of mouse brain to immunoprecipitation using an antibody against the C-terminal 
region of APP, followed by Western blot analysis of the immunoprecipitates using 
anti-SUMO-1 or anti-SUMO-2 antibodies.  The results of this experiment, shown in 
Figure 3.4, indicate that brain APP is modified by SUMO-1 and SUMO-2. 
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Section 3.3.4 Up-regulating the sumoylation machinery inhibits the 
generation of Aβ aggregates 
 
Based on the above results indicating that blocking sumoylation of APP results in 
elevated levels of Aβ peptide aggregates, we hypothesized that up-regulating cellular 
sumoylation could represent a means for reducing Aβ levels.  To test this hypothesis, we 
determined the effect of up-regulating expression of ubc9, the SUMO E2 enzyme, on 
levels of Aβ aggregates in cells transfected with an APP construct containing the familial 
Alzheimer’s disease-associated V642F mutation that results in elevated levels of Aβ 
aggregates (106, 121).   
 
Thus, in this experiment cells were transfected with a 6xHis-APP (V642F) 
construct and the HA-SUMO-1 construct, and either an empty pcDNA3 plasmid or a 
pcDNA3 construct that expresses ubc9, the SUMO E2 enzyme.  The 6xHis-APP 
(V642F) protein was isolated from extracts of the transfected cells using Ni-NTA affinity 
beads and then analyzed by anti-HA Western blot to detect sumoylated forms of this 
protein.  The results of this experiment indicate that the amount of sumoylation of this 
APP protein is higher in the ubc9-overexpressing cells (Figure 3.5 a), and that this is 
associated with decreased amounts of Aβ aggregates in extracts of these cells (Figure 3.5 
b). 
 
Section 3.3.5 The SUMO E2 enzyme is present within the endoplasmic 
reticulum 
 
The SUMO enzymes have only been identified in nuclei and cytosol, and 
sumoylation of protein domains that are exposed to the lumen of the endoplasmic 
reticulum (ER) or other compartments of the secretory pathway has not been previously 
reported.  However, the results described above indicating the SUMO modification of 
 62
lysines 587 and 595 in the outer cell membrane domain of APP suggest that sumoylation 
may be occurring within one or more of the membrane-bound compartments of the 
secretory pathway.  
 
To test the feasibility of this hypothesis, we performed immunofluorescence 
analysis of cells using antibodies against the SUMO E2 enzyme, ubc9, as well as the ER 
protein calnexin.  The results of this analysis indicate that a portion of the ubc9 staining 
in cells overlaps that of calnexin (Figure 3.6 a and 3.6 b), suggesting that this 
sub-population of the SUMO E2 enzyme co-localizes with the ER.  The ubc9 staining 
pattern we observed is consistent with the results of previous studies which showed that, 
in addition to a nuclear-localized population, some of the ubc9 staining is found outside 
the nucleus in a pattern reminiscent of ER localization (80, 122, 123). 
 
As an independent approach for testing the apparent co-localization of ubc9 with 
the ER, Western blot analysis was performed on nuclear vs. ER vesicle-enriched 
membrane fractions using antibodies against ubc9 as well as antibodies against lamin A 
and calnexin as positive controls for the nuclear and ER fractions, respectively.  The 
results of this experiment indicate that a portion of the cellular ubc9 localizes in the ER 
vesicle fraction, both uncharged ubc9 and ubc9 that is covalently charged with SUMO, 
the form of the protein ready to transfer the SUMO group to other proteins (Figure 3.7 a).  
These results support the hypothesis that the SUMO E2 enzyme is associated with the 
ER. 
 
For ubc9 to be able to sumoylate APP, it would presumably have to be present 
within the lumenal compartment of the secretory pathway.  To test this hypothesis we 
subjected sealed calf brain microsomes enriched in rough ER to trypsin digestion in the 
absence or presence of Triton X-100, with the detergent functioning to unseal the vesicles 
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to expose their contents to the protease.  The results of this experiment reveal that in the 
absence of Triton X-100 no degradation of ubc9 is observed, but the presence of Triton 
X-100 results in digestion of the ubc9 protein (Figure 3.7 b).  These results suggest that 
the SUMO E2 enzyme localizes within the lumen of ER vesicles.  The results also 
indicate that both uncharged ubc9, as well as a substantial amount of active 
SUMO-charged ubc9, are found within this compartment. 
 
Section 3.4 Discussion 
Section 3.4.1 Sumoylation of APP inhibits generation of Aβ aggregates 
 
The results decribed above indicate that lysines 587 and 595 of the APP protein 
are covalently modified by both SUMO-1 and SUMO-2, and that this modification 
functions as a negative regulator of levels of Aβ aggregates.  The mechanism by which 
sumoylation at lysines 587 and 595 leads to decreased Aβ aggregate levels is unknown, 
but the close proximity of the sumoylation sites to the site of β-secretase cleavage 
suggests the possibility that the presence of the 97 amino acid SUMO protein attached at 
these sites might sterically block binding of β-secretase to APP (Figure 3.8). 
 
Besides sterical effect, we cannot exclude other possibilities that may be 
responsible for the inhibitory effect of APP sumoylation on the generation of Aβ 
aggregates.  SUMO proteins on lysines 587 and 595 may bind β-secretase, and even 
inhibit its function, protecting β-cleavage site of APP from being recognized by 
β-secretase.  Further studies could be performed to compare the ability of wildtype and 
mutant APP proteins to bind with β-secretase, and enzyme activity of β-secretase in cells 
expressing APP wildtype or mutant proteins.   
 
 64
One of the lysine residues identified as a sumoylation site by this study, lysine 
595, is the same lysine that is mutated to asparagine in the previously characterized 
Swedish (KM-to-NL) APP mutant.  This suggests the possibility that inability to be 
sumoylated at this lysine could contribute, at least to some extent, to the increased Aβ 
production exhibited by the Swedish APP mutant.   
 
Two previous studies obtained data indicating that overexpression of SUMO 
proteins affects the levels of Aβ (124, 125).  However, these studies did not examine 
whether APP was sumoylated, and in addition the meaning of these results is not clear as 
the two studies observed opposite effects of SUMO protein overexpression on Aβ levels.  
In any event, it appears these effects of SUMO overexpression on Aβ are likely mediated 
by a mechanism different from that of direct APP sumoylation examined in our study as 
they were observed even when non-conjugatable SUMO proteins were expressed (125). 
 
It was noted, with respect to the single sumoylation site K587R and K595R 
mutants vs. wildtype APP, that the decrease of levels of protein sumoylation for these 
single sumoylation site mutants is not dramatic.  This can be explained by the fact that  
α-cleavage occurs at the cell surface, and APPα is secreted into the extracellular medium 
(97).  The majority of APP wildtype proteins are processed through α-cleavage pathway, 
and sumoylated APPα cannot be detected in the cell lysate.  On the contrary, although 
K587R and K595R mutant APP proteins can only be sumoylated at one site, sumoylated 
APPβ retains inside the cell because β-cleavage happens intracellularly.  The 
sumoylated APP proteins detected include both APP whole protein and APPβ, this could 
explain why there is no dramatic difference between the sumoylation levels of wildtype 
APP and the single sumoylation site mutants. 
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It has been found that the production of Aβ from Swedish mutant is by a cellular 
mechanism different from that responsible for the production of Aβ from wildtype APP 
protein.  Aβ production from Swedish mutant occurs in Golgi-derived vesicles (102, 
126), however, the production of Aβ from wildtype APP requires reinternalization via 
endocytosis into the endosomal/lysosomal system (127).  Based on our model, loss of 
sumoylation of Swedish mutant allows the binding of β-secretase in Golgi vesicles, and 
results in the generation of Aβ.  Sumoylation of wildtype APP in ER blocks the binding 
of β-secretase in the secretory pathway, however, reinternalization into the 
endosomal/lysosomal system may result in loss of sumoylation, which could be 
responsible for the small amount of Aβ generated from wildtype APP. 
 
Section 3.4.2 Up-regulating sumoylation machinery could be a potential 
therapeutic approach against AD 
 
The results indicating that elevation of ubc9 expression reduces levels of Aβ 
aggregates in cells expressing APP V642F suggest that approaches that up-regulate 
cellular sumoylation have potential as new therapeutic strategies against Alzheimer’s 
disease. 
 
Familial AD patients with mutations in APP or proteins associated with APP 
processing only comprise 10% of all AD cases.  The high incidence of AD in aged 
people suggests that the sumoylation machinery may be down-regulated in aged people.  
In one group of experiments, I compared the levels of SUMO-1, SUMO enzymes E1 and 
ubc9 in brain tissues of young vs. old mice.  And the results (not shown) verified our 
assumption.  The levels of SUMO-1 and SUMO enzymes are lower in brain tissues of 
old mice.  The down-regulation of sumoylation machinery resembles the finding that 
heat-induced hsp70 expression is reduced with increasing of age (47, 48).  As discussed 
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previously, hsp70 can help protein folding and prevent protein aggregation.  So, 
down-regulation of sumoylation machinery and heat shock protein expression could 
cooperatively result in accumulation of Aβ aggregates in aged people. 
 
If the decreased level of protein sumoylation in aged people is verified in further 
studies, our findings that expressing ubc9 up-regulates APP sumoylation and inhibits the 
production of Aβ could have great implications in the treatment of AD. 
 
A number of factors affect the production of Aβ and pathogenesis of AD.  Aging 
is probably the most important one.  Besides the possibility of reduced level of protein 
sumoylation in aged people as discussed above, another example that aging could affect 
the production of Aβ is that GM1 level in lipid rafts of synaptosomes increases with age 
(128).  It has been found that Aβ bound to GM1 ganglioside can act as a nucleation seed 
for Aβ aggregation (129, 130), so increased level of GM1 accelerates the accumulation of 
Aβ aggregates. 
 
Another factor associated with AD is oxidative stress.  Increased free radical 
generation, lipid peroxidation, DNA and protein oxidation have been observed in AD 
brain.  It has been reported that oxidative stress results in accumulation of Aβ in human 
neuroblastoma cells (131).  Conversely, accumulation of Aβ can impair the function of 
mitochondria, induce the generation of free radicals, and result in the oxidative damage 
(132). 
 
Oxidative stress has also been reported to inhibit protein sumoylation, probably 
by formation of a reversible disulfide bridge between the catalytic cysteines of the 
SUMO E1 subunit uba2 and the E2 enzyme ubc9 (133).  So the oxidative stress in AD 
patients could result in decreased sumoylation of APP and increased generation of Aβ. 
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Section 3.4.3 Ubc9 exists in the lumen of ER 
 
The data presented in this paper also indicates that the SUMO E2 enzyme ubc9 is 
present within the lumen of the endoplasmic reticulum, providing an explanation for how 
lysines 587 and 595 of APP can be sumoylated, and suggesting that other proteins 
entering the endoplasmic reticulum may also be targets of sumoylation.  The mechanism 
by which ubc9 enters this compartment is unclear, as it does not appear to contain any 
obvious signal sequence.  However, ubc9 is identified as a candidate non-classical 
secretory pathway protein by the prediction program SecretomeP (134).   
 
Thus, one possibility is that ubc9 enters some endosomal vesicles which then 
subsequently merge with the ER (135).  SUMO-charged ubc9 proteins found within the 
ER compartment then transfer SUMO to the sumoylation sites of APP which face the 
lumen of ER.   
 
The findings that ubc9 exists in the lumen of ER extend the sub-cellular reach of 
sumoylation to include the regulation of proteins in the secretory pathway.  Further 
studies are needed to verify if ubc9 enters ER through non-classical secretory pathway, 
and if it is ture, ubc9 can be secreted to the extracellular medium, and we can even 
imagine that sumoylation occurs at the outer surface of the cell membrane and in the 
extracellular medium. 
 
As a following project, we are trying to identify other sumoylated proteins in the 
lumen of ER.  Immunoprecipitation has been performed with ER vesicles using 
SUMO-1 or SUMO-2 antibodies, and the proteins in the IP product will be identified by 
mass spectrometry.  The newly identified proteins in the secretory pathway will provide 
us a lot of new information about protein sumoylation and other cellular processes. 
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Figure 3.1 Proteolytic cleavage of amyloid precursor protein (APP).  This figure is from 
Wilson et al. (1999) (136). 
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Figure 3.2 APP is sumoylated by SUMO-1 at lysines 587 and 595 of APP, and 
sumoylation at these sites negatively regulates levels of Aβ aggregates.  (a) Schematic 
showing locations of matches to the sumoylation consensus sequence (ΨKXE/D) 
surrounding lysines 587 and 595 in APP695.  Also indicated is the proximity of these two 
lysine residues to the site of β-cleavage and the Aβ peptide generated from APP.  (b) 
HeLa cells were transfected with 6xHis-APP wildtype or mutant APP (K587R, K595R, 
or K587, 595R) constructs along with an HA-SUMO-1 expression plasmid.  APP 
protein was pulled down from extracts of the transfected cells using Ni-NTA agarose 
affinity chromatography, followed by Western blot using anti-HA antibody to detect the 
sumoylated forms of the transfected proteins.  (c) The amount of Aβ aggregates present 
in extracts of each of the transfected cell populations was examined by performing 
Western blot using an anti-Aβ(1-17) mouse monoclonal antibody.  (d) As a loading and 
normalizing control, the amount of full-length APP protein in the cell lysate was 
determined by Western blot using an anti-APP C-terminal rabbit polyclonal antibody. 
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Figure 3.3 APP is sumoylated by SUMO-2 at lysines 587 and 595 of APP, and 
sumoylation at these sites negatively regulates levels of Aβ aggregates.  These 
experiments were performed as described in the legend of Figure 3.1, except that here the 
cells were transfected with an HA-SUMO-2 expression construct instead of HA-SUMO-1 
construct, along with the wildtype and lysine mutant 6xHis-APP plasmids.  (a) Results 
of anti-HA Western blot analysis of the 6xHis-APP proteins isolated from the transfected 
cell extracts to detect the SUMO-2 containing forms of these proteins.  (b) Western blot 
analysis of levels of Aβ aggregates present in extracts of each transfected cell population.  
(c) Western blot assay of these extracts using the anti-APP C-terminal antibody to 
measure levels of full-length APP. 
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Figure 3.4 Endogenous brain APP is sumoylated.  Extracts of mouse brain were 
subjected to immunoprecipitation using an antibody against the C-terminal region of APP, 
followed by Western blot analysis of the immunoprecipitates using anti-SUMO-1 or 
anti-SUMO-2 antibodies. 
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Figure 3.5 Elevated expression of SUMO E2 in cells reduces amounts of Aβ aggregates.  
(a) HeLa cells were transfected with a 6xHis-APP V642F construct and an HA-SUMO-1 
expression plasmid, along with either empty pcDNA3 or a pcDNA3-ubc9 expression 
construct.  APP protein was pulled down from cell extracts using Ni-NTA agarose 
affinity chromatography, followed by Western blot using anti-HA antibody to detect the 
sumoylated forms of the transfected APP protein.  (b) Up-regulation of ubc9 expression 
in the cells transfected with the pcDNA3-ubc9 plasmid was confirmed by Western blot 
assay using anti-ubc9 antibody.  (c) The amount of Aβ aggregates present in extracts of 
each of the transfected cell populations was examined by performing Western blot using 
an anti-Aβ(1-17) mouse monoclonal antibody.  (d) As a loading and normalizing control, 
the amount of full-length APP protein in the cell lysate was determined by Western blot 
assay using an antibody against the C-terminal region of APP. 
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Figure 3.6 A sub-population of ubc9 co-localizes with ER marker protein calnexin.  (a) 
HeLa cells were subjected to immunofluorescence microscopy using antibodies against 
ubc9 and the ER marker protein calnexin.  DNA was visualized by staining with 
Hoechst 33342.  (b) A higher magnification view of a cell using the same visualizations 
in panel A is shown. 
 
 
 74
Figure 3.7 The SUMO E2 enzyme is present within the ER lumenal compartment.  (a) 
Nuclei and a membrane fraction enriched in large dense ER vesicles were prepared from 
HeLa cells, and then these fractions were subjected to Western blot assay using 
antibodies against the SUMO E2 enzyme ubc9, as well as with antibodies against the 
lamin A and calnexin proteins as positive controls for the nuclear and ER compartments, 
respectively.  (b) Calf brain microsomes enriched in rough ER were subjected to trypsin 
digestion for 30 minutes in the absence or presence of Triton X-100, and then analyzed 
by SDS-PAGE and Western blot using antibodies against ubc9.  The lane marked “C” 
represents an aliquot of the microsomes used for this experiment. 
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Figure 3.8 A model proposed to explain the negative regulation of levels of Aβ 
aggregates by APP sumoylation.  (a) SUMO proteins attached at lysines 587 and 595 of 
APP sterically block the binding of β-secretase to this protein, and inhibit the generation 
of Aβ from APP.  (b) Loss of sumoylation allows the binding of β-secretase to APP, and 
in this way, APP can be cleaved by either α-cleavage or β-cleavage pathway, allowing the 
generation of Aβ aggregates.  Loss of sumoylation can be caused by mutations of APP 
at the sumoylation sites, or down-regulation of sumoylation machinery associated with 
age. 
 
Copyright © Yu-Qian Zhang 2008 
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Chapter 4 Concluding Remarks 
 
In this dissertation, I have described and discussed three different projects.  
Chapter 1 is about polyglutamine diseases and the heat shock response, Chapter 2 is 
about lamin A sumoylation and cardiomyopathy, and Chapter 3 addresses APP 
sumoylation and Alzheimer’s disease.  These three projects involve different cellular 
processes, such as the heat shock response, protein sumoylation, and proteolytic cleavage, 
and different human diseases, including polyglutamine diseases, laminopathies, and 
Alzheimer’s disease. 
 
In the first project, my results show that celastrol, a small pharmacological 
compound capable of inducing the heat shock response, can protect against expanded 
polyglutamine caused protein aggregation and cytotoxicity.  In the second project, my 
results indicate that laminopathy associated lamin A mutations cause loss of sumoylation 
of lamin A, and mutant lamin A proteins form foci in the nuclei.  And the results of my 
third project demonstrate that amyloid precursor protein is sumoylated, and loss of 
sumoylation could result in increased generation of Aβ aggregates.  These three projects 
are independent of each other, but to think it further, they share something in common.   
 
Cells exert different cellular mechanisms to protect against protein misfolding and 
aggregation, and impairment of these cellular mechanisms will cause protein 
mislocalization, aberrant proteolytic cleavage, accumulation of aggregates, and other 
severe cytotoxicities, such as impairment of the ubiquitin-proteasome system, and 
disruption of normal protein interactions and cellular functions, finally resuling in 
damage to brain, heart or other tissues. 
 
The heat shock response and protein sumoylation are two cellular mechanisms 
that exert protective effects.  It has been reported that the levels of the heat shock 
 77
 78
proteins are decreased in aged people (47, 48), and our own study has shown that the 
sumoylation machinery is down-regulated in old mice.  Impairment of these cellular 
protective mechanisms could be partly responsible for the aging associated diseases such 
as polyglutamine diseases and Alzheimer’s disease.   
 
Induction of the heat shock response by small pharmacological compound such as 
celastrol, and up-regulating the sumoylation machinery by some small molecule or by 
infection of the virus expressing SUMO enzymes could be potential therapeutic 
approaches for these aging diseases.  For lamin A E203 mutation caused familial dilated 
cardiomyopathy, up-regulating the levels of SUMO enzymes, such as specific E3 ligase, 
may overcome the decreased sumoylation efficiency caused by E203 mutations in the 
sumoylation concensus sequence of lamin A.   
 
It has also been reported that aging is associated with decreased proteasome 
activity, including decreased subunit expression and impaired 26S proteasome assembly 
(137-141).  The impaired proteasome activity could exacerbate the accumulation of 
toxic proteins.  Above all, down-regulations of the heat shock response, protein 
sumoylation, and proteasome activity could cooperatively contribute to the aging diseases.  
These cellular processes are also correlated with each other, for example, sumoylation 
has been reported to regulate the function of heat shock factor 1 (142), it has also been 
reported that proteasome inhibitor can induce the heat shock response (143) and result in 
accumulation of SUMO-2/3 conjugated proteins (144).  
 
Further study of these cellular protective mechanisms and the interactions 
between these pathways could provide us a lot of insightful information in the battle 
against aging. 
Copyright © Yu-Qian Zhang 2008
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